[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 355
6. Dierickx D, Wlodarska I, Vanhentenrijk V, De Wolf-Peeters C, Devos T, Delforge M, Janssens A, Maertens J, Thomas J, Verhoef G: Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphoma. Leuk Lymphoma; 2008 Dec;49(12):2365-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphoma.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Cyclin D1 / deficiency. Lymphoma, Mantle-Cell / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Invasiveness


7. Mahfouz S, Aziz AA, Gabal SM, el-Sheikh S: Immunohistochemical study of CD99 and EMA expression in ependymomas. Medscape J Med; 2008;10(2):41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the central nervous system (CNS) represent a unique, heterogeneous population of neoplasms and include both benign and malignant tumors.
  • The present study was carried out on a total of 79 archival cases of ependymal tumors in addition to a variety of other primary CNS tumors.
  • Upon comparing with other CNS tumors (41 cases), it was found that CD99 could differentiate between ependymomas and nonependymal tumors, but intensity and pattern of staining were of no consequence in determining variant type or degree of histologic aggressiveness.
  • CD99 can hence be recommended for use as a good marker for differentiation between ependymal and other CNS tumors.
  • EMA expression and pattern of distribution, on the other hand, cannot be employed to determine the type of variant or the degree of tumor aggressiveness, and hence cannot predict the behavior of ependymal neoplasms.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cell Adhesion Molecules / analysis. Ependymoma / diagnosis. Ependymoma / metabolism. Mucin-1 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Proteins / analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):25-31 [10937045.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):125-9 [11396629.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):247-50 [11933271.001]
  • [Cites] J Neurooncol. 2002 May;58(1):13-9 [12160136.001]
  • [Cites] Exp Mol Med. 2002 Jul 31;34(3):177-83 [12216109.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):385-8 [12898159.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):980-91 [14559980.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):517-23 [14585232.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1230-7 [15022291.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Mar;63(3):185-92 [15055442.001]
  • [Cites] Neuropathol Appl Neurobiol. 1988 May-Jun;14(3):197-205 [3405393.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6127-31 [2844401.001]
  • [Cites] Acta Neuropathol. 1989;78(3):325-8 [2763805.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(2):97-103 [1695040.001]
  • [Cites] Arch Pathol Lab Med. 1990 Sep;114(9):956-60 [2390011.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Acta Neuropathol. 1991;82(3):208-16 [1718129.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):189-93 [15690137.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):17-21 [15696964.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Histopathology. 2007 Feb;50(3):365-70 [17257132.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):255-70 [12187959.001]
  • [Cites] Acta Neuropathol. 1997 Mar;93(3):310-6 [9083565.001]
  • [Cites] Neuropathology. 2004 Dec;24(4):330-5 [15641594.001]
  • [Cites] Pathol Res Pract. 2004;200(10):717-25 [15648610.001]
  • (PMID = 18382710.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Mucin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2270873
  •  go-up   go-down


8. Marsh GM, Buchanich JM, Youk AO, Cunningham MA, Lieberman FS, Kennedy KJ, Lacey SE, Hancock RP, Esmen NA, Fleissner ML: Long-term health experience of jet engine manufacturing workers: III. Incidence of malignant central nervous system neoplasms. Neuroepidemiology; 2010 Aug;35(2):123-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term health experience of jet engine manufacturing workers: III. Incidence of malignant central nervous system neoplasms.
  • We identified 722 cases of CNS neoplasms mainly by tracing through 19 state cancer registries.
  • CONCLUSIONS: Incidence rates for glioblastoma and other malignant CNS neoplasm histologies were not elevated in the total cohort.
  • [MeSH-major] Aviation. Central Nervous System Neoplasms / epidemiology. Glioblastoma / epidemiology. Industry. Occupational Diseases / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Cause of Death. Cohort Studies. Connecticut / epidemiology. Female. Humans. Male. Middle Aged. Occupational Exposure / adverse effects. Population. Radiation. Registries. Risk Assessment. Risk Factors. United States / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20523076.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Manders K, van de Poll-Franse LV, Creemers GJ, Vreugdenhil G, van der Sangen MJ, Nieuwenhuijzen GA, Roumen RM, Voogd AC: Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer; 2006;6:179
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Before they died, 70% of the 116 patients developed metastases in one or more bones, 50% in the lung and/or pleura, 50% in the abdominal viscera, 23% in the central nervous system, and 19% in the skin.
  • Patients younger than 50 years were much more likely to develop metastases in the central nervous system than patients 50 years and older.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy
  • [MeSH-minor] Adult. Age Distribution. Aged. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis / pathology. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998;77(2):336-40 [9461007.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):671-9 [8636786.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(1):67-78 [10517344.001]
  • [Cites] Cancer Treat Rev. 2005 Jun;31(4):312-8 [15979804.001]
  • [Cites] J Clin Epidemiol. 1999 Dec;52(12):1131-6 [10580775.001]
  • [Cites] Breast Cancer Res Treat. 2000 Feb;59(3):271-8 [10832597.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):81-7 [11249054.001]
  • [Cites] Breast Cancer Res Treat. 2001 Feb;65(3):233-40 [11336245.001]
  • [Cites] Eur J Cancer. 2000 Dec;36(18):2301-12 [11094303.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):197-207 [11885995.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(11):1466-73 [12110492.001]
  • [Cites] Cancer. 2002 May 15;94(10):2698-705 [12173339.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):545-53 [12548595.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):207-10 [14760110.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2):234-48 [15112153.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):810-6 [15305414.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3302-8 [15310773.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Aug;16(5):345-9 [15341438.001]
  • [Cites] BMJ. 1989 Jan 7;298(6665):13-4 [2492839.001]
  • [Cites] Br J Cancer. 1992 Mar;65(3):449-55 [1558803.001]
  • [Cites] JAMA. 1992 Jul 1;268(1):57-62 [1608114.001]
  • [Cites] J Natl Cancer Inst. 1994 Dec 7;86(23):1766-70 [7966414.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):232-6 [8625097.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1030-5 [9508187.001]
  • (PMID = 16824210.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1534056
  •  go-up   go-down


10. Tucci E, Della Rocca C, Santilli F: Localized bacillary angiomatosis in the oral cavity: observations about a neoplasm with atypical behavior. Description of a case and review of the literature. Minerva Stomatol; 2006 Jan-Feb;55(1-2):67-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized bacillary angiomatosis in the oral cavity: observations about a neoplasm with atypical behavior. Description of a case and review of the literature.
  • Bacillary angiomatosis is a rather frequent infectious pathology appearing mainly in the skin but can also affect the liver, spleen, heart, bones, lungs, muscles, central nervous system and other organs.
  • [MeSH-minor] Adolescent. Adult. Ampicillin / analogs & derivatives. Ampicillin / therapeutic use. Bartonella henselae / pathogenicity. Bartonella quintana / pathogenicity. Child. Chlorhexidine / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Gingival Neoplasms / diagnosis. Granuloma, Pyogenic / diagnosis. Hemangioendothelioma, Epithelioid / diagnosis. Hemangiosarcoma / diagnosis. Humans. Male. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Recurrence. Sarcoma, Kaposi / diagnosis. Tooth Extraction

  • Hazardous Substances Data Bank. CHLORHEXIDINE .
  • Hazardous Substances Data Bank. AMPICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16495874.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 7C782967RD / Ampicillin; 8GM2J22278 / bacampicillin; R4KO0DY52L / Chlorhexidine
  •  go-up   go-down


11. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson M, Wilson WH: High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood; 2005 Jan 15;105(2):496-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.
  • We assessed the cerebrospinal fluid (CSF) by flow cytometry and cytology in 51 newly diagnosed and 9 treated aggressive B-cell lymphomas at risk for central nervous system (CNS) involvement to examine the utility of flow cytometry, incidence of CSF disease, and clinical surrogates of CNS spread.
  • We hypothesize that the biologic phenotype associated with colonization of extranodal sites leads to CNS spread, possibly related to the microenvironment.
  • Patients at risk for CNS spread should undergo staging CSF evaluation by flow cytometry.
  • [MeSH-major] Flow Cytometry / methods. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Meningeal Neoplasms / epidemiology. Meningeal Neoplasms / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Incidence. Male. Middle Aged. Pathology, Clinical / methods. Prognosis. Recurrence. Risk Factors. Sensitivity and Specificity

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15358629.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Eralp Y, Saip P, Aydin Z, Berkman S, Topuz E: Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol; 2008 Jan;108(1):248-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dissemination of ovarian cancer occurs mainly within the peritoneal cavity and central nervous system involvement (CNS) is encountered rarely.
  • [MeSH-major] Meningeal Neoplasms / secondary. Neoplasm Seeding. Ovarian Neoplasms / pathology. Ventriculoperitoneal Shunt / adverse effects
  • [MeSH-minor] Adult. Female. Humans. Hydrocephalus / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961641.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Jahnke K, Korfel A, Komm J, Bechrakis NE, Stein H, Thiel E, Coupland SE: Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol; 2006 Jun;244(6):663-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nineteen patients had primary IOL (PIOL): 13 a newly diagnosed disease and six an ocular relapse of primary central nervous system lymphoma (PCNSL).
  • [MeSH-major] Brain Neoplasms / pathology. Eye Neoplasms / pathology. Lymphoma / pathology. Retinal Neoplasms / pathology. Vitreous Body / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Alkylating / therapeutic use. Cyclophosphamide / analogs & derivatives. Cyclophosphamide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Surveys and Questionnaires. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Dec 1;62(11):2461-5 [3179963.001]
  • [Cites] Surv Ophthalmol. 1975 Jan-Feb;19(4):224-39 [1089323.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):556-64 [8636771.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Sep;242(9):771-6 [15349786.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):843-9 [8334638.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):1985-92 [9815588.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1805-10 [10485554.001]
  • [Cites] Ophthalmology. 1988 May;95(5):625-30 [3050698.001]
  • [Cites] Ocul Immunol Inflamm. 2000 Dec;8(4):243-50 [11262654.001]
  • [Cites] Br J Ophthalmol. 2005 Feb;89(2):238-9 [15665359.001]
  • [Cites] Cancer. 1989 May 15;63(10):1918-21 [2702565.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Anticancer Drugs. 1997 Jun;8(5):419-31 [9215603.001]
  • [Cites] Ophthalmology. 2001 Feb;108(2):386-99 [11158819.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):711-5 [12576439.001]
  • [Cites] Eye (Lond). 2003 May;17(4):513-21 [12802353.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1709-16 [12208721.001]
  • [Cites] Ann Intern Med. 1993 Dec 1;119(11):1093-104 [8239229.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):742-9 [11157026.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1359-70 [11002232.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):137-42 [11307054.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):559-63 [10078637.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):684-92 [15497122.001]
  • [Cites] Ophthalmology. 1993 Sep;100(9):1399-406 [8371930.001]
  • [Cites] Ocul Immunol Inflamm. 2004 Mar;12(1):7-16 [15209459.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Nov;242(11):901-13 [15565454.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):531-8 [12056702.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1762-7 [15350334.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2003 Oct;241(10):860-70 [14605902.001]
  • (PMID = 16228920.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; H64JRU6GJ0 / trofosfamide; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


1
Advertisement
4. Chen YY, Tiang XY, Li Z, Luo BN, Huang Q: Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature. Diagn Pathol; 2010;5:39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No tumor recurrence was found during this period.
  • [MeSH-major] Brain Neoplasms / diagnosis. Central Nervous System Vascular Malformations / diagnosis. Cerebral Cortex / pathology. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Apr;92(4):706-10 [10761664.001]
  • [Cites] Acta Cytol. 2009 Jan-Feb;53(1):93-7 [19248561.001]
  • [Cites] Pediatr Dev Pathol. 2001 Nov-Dec;4(6):568-72 [11826364.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):48-56 [11849563.001]
  • [Cites] Nervenarzt. 2002 Oct;73(10):990-4 [12376888.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Apr;29(2):170-4 [12662324.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):643-5 [14655769.001]
  • [Cites] Am J Clin Pathol. 1974 Oct;62(4):481-7 [4212953.001]
  • [Cites] J Neurosurg. 1982 Jan;56(1):154-7 [7054414.001]
  • [Cites] Acta Neuropathol. 1987;73(4):361-4 [3618128.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):715-9 [2213161.001]
  • [Cites] Pathol Res Pract. 1992 Feb;188(1-2):145-7 [1594484.001]
  • [Cites] J Neurosurg. 1993 Feb;78(2):287-9 [8421212.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):485-9 [9143261.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):872-5 [10435554.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Childs Nerv Syst. 2006 Jan;22(1):78-83 [16389566.001]
  • [Cites] Surg Neurol. 2006 Jun;65(6):595-603 [16720184.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):125-9 [11756780.001]
  • (PMID = 20565869.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2904739
  •  go-up   go-down


15. Sibtain NA, Butt S, Connor SE: Imaging features of central nervous system haemangiopericytomas. Eur Radiol; 2007 Jul;17(7):1685-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging features of central nervous system haemangiopericytomas.
  • [MeSH-major] Cerebral Angiography. Hemangiopericytoma / diagnosis. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Brain / pathology. Diagnosis, Differential. Dura Mater / blood supply. Dura Mater / pathology. Follow-Up Studies. Humans. Magnetic Resonance Angiography. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Pericytes / pathology. Sensitivity and Specificity. Spinal Cord Compression / diagnosis. Spinal Cord Compression / surgery

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Neurol. 1984;23(4):274-7 [6489389.001]
  • [Cites] Am J Surg. 1992 May;163(5):490-3 [1575304.001]
  • [Cites] Neuroradiology. 1994 Aug;36(6):440-5 [7991087.001]
  • [Cites] Neurosurgery. 2002 Mar;50(3):654-7 [11841738.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):359-62 [9950509.001]
  • [Cites] Surg Neurol. 2003 Jan;59(1):47-53; discussion 53-4 [12633961.001]
  • [Cites] AJNR Am J Neuroradiol. 1981 Jan-Feb;2(1):69-74 [6784553.001]
  • [Cites] Neurology. 1961 Jun;11:497-502 [13773875.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1491-7 [15042684.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(6):575-86 [11534674.001]
  • [Cites] J Neurosurg. 1970 May;32(5):539-44 [5461885.001]
  • [Cites] Ann Surg. 1942 Jul;116(1):26-33 [17858068.001]
  • [Cites] Eur J Surg Oncol. 1997 Aug;23(4):282-5 [9315052.001]
  • [Cites] Radiology. 1980 Sep;136(3):665-75 [7403545.001]
  • [Cites] Neurosurgery. 1989 Oct;25(4):514-22 [2797389.001]
  • [Cites] Neuroradiology. 2004 Mar;46(3):194-7 [14991259.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Aug;17(7):1365-71 [8871726.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Dec;125(4):823-32 [1211512.001]
  • [Cites] Surg Neurol. 1985 Mar;23 (3):227-36 [3975803.001]
  • (PMID = 17131127.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Idowu MO, Rosenblum MK, Wei XJ, Edgar MA, Soslow RA: Ependymomas of the central nervous system and adult extra-axial ependymomas are morphologically and immunohistochemically distinct--a comparative study with assessment of ovarian carcinomas for expression of glial fibrillary acidic protein. Am J Surg Pathol; 2008 May;32(5):710-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymomas of the central nervous system and adult extra-axial ependymomas are morphologically and immunohistochemically distinct--a comparative study with assessment of ovarian carcinomas for expression of glial fibrillary acidic protein.
  • We reviewed the morphologic and immunohistochemical features of 5 extra-axial ependymomas occurring in adults, 1 arising in an infantile sacrococcygeal teratoma, and a control group of 10 central nervous system (CNS) ependymomas in adults.
  • The adult extra-axial cases demonstrated more architectural variability than the CNS cases.
  • We observed that both the CNS and adult extra-axial ependymomas expressed GFAP diffusely, whereas only 9 stage III, high-grade ovarian serous papillary carcinomas stained with GFAP (2 strongly and diffusely and 7 exhibiting focally weak expression).
  • There were significant immunophenotypic differences between adult extra-axial and CNS ependymomas, with extra-axial cases preferentially expressing 34betaE12 (60% vs. 0%), CK18 (100% vs. 20%), CAM 5.2 (60% vs. 10%), CK7 (80% vs. 10%), ER (100% vs. 10%), and PR (80% vs. 20%).
  • CNS ependymomas more frequently expressed CD99 (100% vs. 20%).
  • The following stains were not differentially expressed: epithelial membrane antigen (expressed in 2 of 15 cases, including both extra-axial and CNS ependymomas), synaptophysin (1/15), chromogranin (0/15), WT1 (8/15), AE1:3 (10/15), and CK20 (0/15).
  • The ependymal elements of the sacrococcygeal tumor failed to express 34betaE12, CK18, CAM 5.2, and CK7, like most CNS ependymomas.
  • The morphologic and immunophenotypic differences between extra-axial and CNS ependymomas suggest that they derive from distinct precursors and/or differentiate along distinct pathways.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Central Nervous System Neoplasms / metabolism. Ependymoma / metabolism. Glial Fibrillary Acidic Protein / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Immunoenzyme Techniques. Infant. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360284.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


17. Maza S, Kiewe P, Munz DL, Korfel A, Hamm B, Jahnke K, Thiel E: First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol; 2009 Aug;11(4):423-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
  • Most patients with primary CNS lymphoma (PCNSL) relapse after primary therapy.
  • Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood-brain barrier after tumor shrinkage.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Central Nervous System Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Male. Middle Aged. Prognosis. Prospective Studies. Remission Induction. Survival Rate. Tissue Distribution. Yttrium Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):249-57 [10563431.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Eur J Cancer. 1991;27(11):1356-61 [1835848.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Eur J Haematol. 2005 Apr;74(4):348-52 [15777348.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2528-34 [17932895.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1710-1 [15972281.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):53-8 [16283435.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Nov;7(3):236-8 [17229341.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):291-3 [17245621.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1712-20 [17786706.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • (PMID = 19060176.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  • [Other-IDs] NLM/ PMC2743222
  •  go-up   go-down


18. Mehta GU, Shively SB, Gläsker S, Bechert CJ, Zhuang Z, Raffeld M, Lonser RR, Oldfield EH, Vortmeyer AO: von Hippel-Lindau disease: epididymal cystadenoma targeted by metastatic events. Urology; 2007 Jun;69(6):1209.e9-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several investigators have shown these tumors to specifically invade central nervous system hemangioblastomas, which are commonly associated with the disease.
  • We report on multiple metastatic events within a single von Hippel-Lindau disease-associated tumor outside the central nervous system, epididymal cystadenoma.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Epididymis / pathology. Kidney Neoplasms / pathology. Testicular Neoplasms / secondary. von Hippel-Lindau Disease / pathology
  • [MeSH-minor] Adult. Cystadenoma / pathology. Humans. Male. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572225.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


19. Okamura M, Akizuki N, Nakano T, Shimizu K, Ito T, Akechi T, Uchitomi Y: Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychooncology; 2008 Feb;17(2):154-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Algorithms. Antidepressive Agents / therapeutic use. Benzodiazepines / therapeutic use. Depressive Disorder, Major / drug therapy. Depressive Disorder, Major / epidemiology. Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Alprazolam / therapeutic use. Amitriptyline / therapeutic use. Anxiety Disorders / epidemiology. Anxiety Disorders / prevention & control. Anxiety Disorders / psychology. Central Nervous System Stimulants / therapeutic use. Clomipramine / therapeutic use. Disease Progression. Drug Therapy, Combination. Female. Humans. Male. Methylphenidate / therapeutic use. Middle Aged. Neoplasm Staging. Prognosis. Severity of Illness Index

  • Genetic Alliance. consumer health - Major depressive disorder.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • Hazardous Substances Data Bank. ALPRAZOLAM .
  • Hazardous Substances Data Bank. Clomipramine .
  • Hazardous Substances Data Bank. AMITRIPTYLINE HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17461435.001).
  • [ISSN] 1057-9249
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Central Nervous System Stimulants; 12794-10-4 / Benzodiazepines; 1806D8D52K / Amitriptyline; 207ZZ9QZ49 / Methylphenidate; NUV44L116D / Clomipramine; YU55MQ3IZY / Alprazolam
  •  go-up   go-down


20. Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM: Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma; 2005 Dec;46(12):1721-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis.
  • Its natural history, treatment and prognosis have been infrequently characterized in the medical literature; however, a tendency to involve the central nervous system (CNS) has been noted.
  • In British Columbia (population 4 million), a central database for lymphomas has allowed us to accurately track cases of paranasal sinus lymphoma diagnosed since 1980.
  • Following the institution of intrathecal chemotherapy, only 8% (3 of 39) of patients have developed CNS disease.
  • Treatment with combined modality chemotherapy and irradiation can cure many patients and the addition of intrathecal chemotherapy may reduce the risk of CNS relapse.
  • [MeSH-major] Chemoprevention. Lymphoma, Non-Hodgkin / physiopathology. Paranasal Sinus Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Survivors. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263574.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Bradly DP, Reddy VB, Cochran E, Gattuso P: Comparison of cytological features of myxopapillary ependymomas on crush preparations. Diagn Cytopathol; 2009 Aug;37(8):607-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myxopapillary ependymoma (ME) is a rare neoplasm found predominantly in the sacro-coccygeal region in adults and is characterized by its distinct epithelial and stromal components.
  • The epithelial component of ME is strikingly similar for all six cases showing tumor cells appearing singly or in loose clusters, most with papillary branching.
  • These aforementioned characteristics can be utilized to distinguish ME from other primary and metastatic tumors such as meningioma, adenoid cystic carcinoma, chordoma, mucinous adenocarcinoma, chondrosarcoma, and germ cell tumors.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Cytological Techniques / methods. Ependymoma / pathology
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19459157.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Nagane M, Kobayashi K, Ohnishi A, Shimizu S, Shiokawa Y: Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol; 2007 Dec;37(12):897-906
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor tissue from 19 patients was analysed for MGMT protein expression using western blotting, and 17 of them were assessable for a response.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Biomarkers, Tumor / analysis. Central Nervous System Neoplasms / chemistry. Central Nervous System Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioblastoma / chemistry. Glioblastoma / drug therapy. O(6)-Methylguanine-DNA Methyltransferase / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blotting, Western. Child. Disease-Free Survival. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Nitrosourea Compounds / administration & dosage. Predictive Value of Tests. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156172.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 0 / Nitrosourea Compounds; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


23. Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T: Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. Neurosurg Rev; 2010 Apr;34(2):197-208
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomatosis cerebri (GC) is a rare fatal glial neoplasm of the central nervous system.
  • Poor survival showed correlation with higher Ki-67 labeling index, higher choline/N-acetylaspartate ratio on magnetic resonance spectroscopy, tumor volumes, lower Karnofsky performance status on admission, cognitive/behavioral deterioration, poor response to the initial radiochemotherapy, and emergence of paraventricular enhanced lesions during the clinical course.
  • [MeSH-major] Brain Neoplasms / therapy. Neoplasms, Neuroepithelial / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Biopsy. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Fatal Outcome. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Male. Middle Aged. Neurosurgical Procedures. Nimustine / therapeutic use. O(6)-Methylguanine-DNA Methyltransferase / genetics. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Prognosis. Retrospective Studies. Tumor Suppressor Protein p53 / genetics. Young Adult

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2009 Aug 15;115(16):3749-57 [19517475.001]
  • [Cites] Lancet. 2002 Nov 2;360(9343):1361-8 [12423981.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Feb;21(2):375-80 [10696026.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):216-23; discussion 223 [12493121.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1597-606 [16955507.001]
  • [Cites] Radiology. 1989 Aug;172(2):541-8 [2748837.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Sep;61(9):806-14 [12230327.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Neuroradiology. 1996 Nov;38(8):774-7 [8957803.001]
  • [Cites] Radiology. 1993 Mar;186(3):745-52 [8430183.001]
  • [Cites] Neuroradiology. 2000 Aug;42(8):612-5 [10997568.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):53-62 [17018697.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):755-62 [9810441.001]
  • [Cites] J Neurosurg. 2005 Jan;102(1 Suppl):72-7 [16206737.001]
  • [Cites] Clin Neurol Neurosurg. 1987;89(1):43-7 [3568520.001]
  • [Cites] NMR Biomed. 1992 Sep-Oct;5(5):253-8 [1333261.001]
  • [Cites] Neurosurgery. 2007 Jan;60(1):150-8; discussion 158 [17228264.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):103-5 [14716242.001]
  • [Cites] AJR Am J Roentgenol. 1993 Oct;161(4):859-62 [8372774.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):201-5 [16200347.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):204-5 [15277608.001]
  • [Cites] Surg Neurol. 2002 Jun;57(6):399-404; discussion 404 [12176200.001]
  • [Cites] Neuroradiology. 1995 Feb;37(2):99-103 [7761009.001]
  • [Cites] Neurosurgery. 2003 Aug;53(2):261-71; discussion 271 [12925240.001]
  • [Cites] AJR Am J Roentgenol. 2007 Mar;188(3):710-4 [17312058.001]
  • [Cites] Pediatr Neurosurg. 1996 Aug;25(2):94-9 [9075253.001]
  • [Cites] J Comput Tomogr. 1988 Oct;12(4):253-7 [2848658.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Neurology. 2001 Nov 27;57(10 ):1932-3 [11723300.001]
  • [Cites] Clin Neuropathol. 1999 Jul-Aug;18(4):190-7 [10442461.001]
  • [Cites] Eur Radiol. 2001;11(2):309-16 [11218033.001]
  • [Cites] J Child Neurol. 1995 Jan;10(1):37-45 [7539465.001]
  • [Cites] Acta Neurochir (Wien). 2009 Nov;151(11):1349-58 [19730774.001]
  • [Cites] Acta Neurochir (Wien). 1991;113(3-4):131-7 [1799156.001]
  • [Cites] J Neurosurg. 2005 Oct;103(4):702-6 [16266053.001]
  • [Cites] Radiology. 1992 Jun;183(3):701-9 [1584924.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 Dec;38(12):865-70 [10063361.001]
  • [Cites] Eur Radiol. 2001;11(2):303-8 [11218032.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):270-5 [15277619.001]
  • [Cites] Acta Oncol. 2000;39(6):747-51 [11130015.001]
  • [Cites] Neurology. 2004 Jul 27;63(2):354-6 [15277636.001]
  • [Cites] Dev Med Child Neurol. 2001 Feb;43(2):124-6 [11221900.001]
  • [Cites] Neurosurgery. 2006 Jun;58(6):E1209; discussion E1209 [16723870.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3431-7 [16849758.001]
  • [Cites] Clin Neuropathol. 2009 Mar-Apr;28(2):73-82 [19353837.001]
  • [Cites] Rinsho Shinkeigaku. 1995 Apr;35(4):414-9 [7614769.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 May;24(5):946-51 [12748099.001]
  • [Cites] Neurosurgery. 2009 Nov;65(5):866-75; discussion 875 [19834398.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1137-46 [12829152.001]
  • [Cites] Magn Reson Imaging. 2006 Feb;24(2):205-7 [16455411.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4 [14765378.001]
  • [Cites] Radiology. 1992 Dec;185(3):675-86 [1438744.001]
  • [Cites] Surg Neurol. 1991 Dec;36(6):431-40 [1759182.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):646-50 [10653880.001]
  • [Cites] Brain Tumor Pathol. 1998;15(2):111-6 [10328549.001]
  • [Cites] Intern Med. 2003 Jul;42(7):615-8 [12879957.001]
  • [Cites] Int J Clin Oncol. 2010 Aug;15(4):352-8 [20232102.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):2027-31 [12404298.001]
  • [Cites] Eur J Radiol. 1998 Oct;28(3):226-9 [9881257.001]
  • [Cites] J Neurosurg. 2003 Feb;98(2):269-76 [12593610.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3445-53 [12177105.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65 [10782774.001]
  • [Cites] Neurology. 2003 Dec 23;61(12):1796-8 [14694052.001]
  • [Cites] Cogn Behav Neurol. 2003 Sep;16(3):149-59 [14501536.001]
  • (PMID = 21301914.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 0S726V972K / Nimustine; 7GR28W0FJI / Dacarbazine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; YF1K15M17Y / temozolomide
  •  go-up   go-down


24. Kitzmann AS, Pulido JS, Garrity JA, Witzig TE: Histologic findings in T-cell lymphoma infiltration of the optic nerve. Ophthalmology; 2008 May;115(5):e1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 39-year-old man with a diagnosis of peripheral T-cell NHL, stage IV, with CNS involvement and decreased vision was found to have lymphomatous infiltration of the optic nerves.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / pathology. Optic Nerve / pathology
  • [MeSH-minor] Adult. Antigens, CD20 / metabolism. Antigens, CD3 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Visual Acuity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18321583.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


25. Kurian S, Qazilbash M, Fay J, Wolff S, Herzig R, Hobbs G, Bunner P, Weisenborn R, Aya-Ay M, Lynch J, Ericson S: Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. Breast J; 2006 Nov-Dec;12(6):531-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After complete staging, patients with central nervous system or bone marrow involvement were excluded.
  • Hormone receptor status was known in 148 patients, of whom 84 had estrogen receptor (ER) and/or progestrone receptor (PgR)-positive tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Remission Induction. Survival Rate. Transplantation, Autologous


26. Bavaresco L, Bernardi A, Braganhol E, Wink MR, Battastini AM: Dexamethasone inhibits proliferation and stimulates ecto-5'-nucleotidase/CD73 activity in C6 rat glioma cell line. J Neurooncol; 2007 Aug;84(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas are the most common and devastating primary tumors of the adult central nervous system.
  • Dexamethasone, a synthetic glucocorticoid, is commonly co-administered to control edema in the management of brain tumors during chemotherapy and radiotherapy.
  • [MeSH-major] 5'-Nucleotidase / metabolism. Anti-Inflammatory Agents / pharmacology. Brain Neoplasms / enzymology. Dexamethasone / pharmacology. Glioma / enzymology
  • [MeSH-minor] Adenosine Monophosphate / metabolism. Animals. Cell Death / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Protein Kinase C / metabolism. Purines / metabolism. Rats. Signal Transduction / drug effects. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. ADENOSINE 5'-PHOSPHATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):805-9 [8687132.001]
  • [Cites] Anal Biochem. 1986 Sep;157(2):375-80 [2946250.001]
  • [Cites] Am J Reprod Immunol. 2005 Mar;53(3):144-52 [15727569.001]
  • [Cites] Vascul Pharmacol. 2005 Mar;42(4):153-62 [15820441.001]
  • [Cites] J Cell Physiol. 2001 Jan;186(1):19-23 [11147810.001]
  • [Cites] J Neurooncol. 2001 Jan;51(2):105-10 [11386406.001]
  • [Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]
  • [Cites] Drug Metab Dispos. 2006 Jun;34(6):1063-9 [16531474.001]
  • [Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]
  • [Cites] Pharmacol Ther. 2003 Oct;100(1):31-48 [14550503.001]
  • [Cites] Neurology. 1997 Jun;48(6):1704-9 [9191791.001]
  • [Cites] Purinergic Signal. 2006 Jun;2(2):409-30 [18404480.001]
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4A):1585-8 [7979189.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Dec;92(5):375-82 [15698542.001]
  • [Cites] Eur J Pharmacol. 1992 Oct 1;227(2):113-22 [1426027.001]
  • [Cites] Br J Pharmacol. 1997 Jan;120(2):273-81 [9117120.001]
  • [Cites] J Pharmacol Toxicol Methods. 2005 Sep-Oct;52(2):234-43 [16125621.001]
  • [Cites] Genes Dev. 1995 Jul 1;9(13):1608-21 [7628695.001]
  • [Cites] Neuroscience. 2000;96(2):417-25 [10683582.001]
  • [Cites] Cell Tissue Res. 2002 Dec;310(3):257-70 [12457224.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4472-8 [12947007.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Jan;280(1):R25-32 [11124130.001]
  • [Cites] Oncogene. 1998 Sep 24;17(12):1567-75 [9794234.001]
  • [Cites] Trends Pharmacol Sci. 2006 Mar;27(3):166-76 [16487603.001]
  • [Cites] Apoptosis. 1999 Jun;4(3):197-211 [14634282.001]
  • [Cites] Melanoma Res. 2006 Jun;16(3):213-22 [16718268.001]
  • [Cites] BMC Cancer. 2006 Sep 23;6:226 [16995949.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Trends Pharmacol Sci. 2006 Apr;27(4):211-7 [16530853.001]
  • [Cites] Nucleic Acids Res. 1992 Feb 25;20(4):825-9 [1531873.001]
  • [Cites] Cancer Lett. 2003 Aug 20;198(2):211-8 [12957360.001]
  • [Cites] Biochem J. 1992 Jul 15;285 ( Pt 2):345-65 [1637327.001]
  • (PMID = 17453149.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Purines; 415SHH325A / Adenosine Monophosphate; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.13 / Protein Kinase C; EC 3.1.3.5 / 5'-Nucleotidase
  •  go-up   go-down


27. Wang Z, Fan QH, Yu MN, Zhang WM: [Clinicopathologic and immunohistochemical study of atypical teratoid/rhabdoid tumor of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2006 Aug;35(8):458-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic and immunohistochemical study of atypical teratoid/rhabdoid tumor of central nervous system].
  • OBJECTIVE: To study the clinicopathologic features and differential diagnosis of atypical teratoid/rhabdoid tumor (AT/RT) occurring in the central nervous system.
  • The tumor cells were positive for vimentin, CD99, epithelial membrane antigen, cytokeratin, glial fibrillary acidic protein, S-100 protein, neurofilament, desmin and smooth muscle actin.
  • CONCLUSIONS: AT/RT is a highly malignant tumor occurring in the central nervous system.
  • The tumor is characterized by a heterogeneous histologic and immunohistochemical phenotype.
  • It needs to be distinguished from a number of central nervous system tumors, including medulloblastoma, primitive neuroectodermal tumor, germ cell neoplasm and rhabdoid meningioma.
  • [MeSH-major] Brain Neoplasms / pathology. Rhabdoid Tumor / pathology. Teratoma / pathology
  • [MeSH-minor] Actins / analysis. Adult. Antigens, CD / analysis. Cell Adhesion Molecules / analysis. Child, Preschool. Desmin / analysis. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Keratins / analysis. Male. Mucin-1 / analysis. Muscle, Smooth / chemistry. Neurofilament Proteins / analysis. S100 Proteins / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069697.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Neurofilament Proteins; 0 / S100 Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


28. Abe T, Kitajima T, Honma K, Kurasaki T, Okazuka K, Shibasaki Y, Momoi A, Kuroha T, Masuko M, Yagisawa K, Furukawa T, Toba K, Aizawa Y: [Effective combination chemotherapy with rituximab for acute lymphoblastic leukemia with bone relapse after bone marrow transplantation]. Rinsho Ketsueki; 2008 Nov;49(11):1556-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initially, ALL relapsed in the central nervous system (CNS) 1 year after transplantation.
  • Then, ALL relapsed as a single bone tumor involving the CNS and pelvis 4 years after transplantation.
  • Finally, multiple bone tumors in the pelvis and lumbar bones were found as well as spread to the bone marrow 5 years after transplantation.
  • Flow cytometry analyses detected CD20-positive cells in the bone tumor.
  • Though the initial bone tumor was resistant to hyper CVAD, radiation was effective and this patient achieved complete remission.
  • After the third relapse, bone marrow achieved complete remission with the administration of pirarubicin, vincristine, prednisolone, and L-asparaginase (arranged DVP-L), though this combination chemotherapy itself was not effective in multiple bone tumors.
  • Thereafter, arranged DVP-L plus rituximab was administered, which resulted in significant tumor reduction.
  • Biweekly rituximab administration as maintenance therapy has completely prevented the regrowth of bone tumors.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Bone Marrow Transplantation. Bone Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047788.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


29. Nguyen QN, Chang EL, Allen PK, Maor MH, Ater JL, Mahajan A, Wolff JE, Weinberg JS, Woo SY: Focal and craniospinal irradiation for patients with intracranial germinoma and patterns of failure. Cancer; 2006 Nov 1;107(9):2228-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective review was conducted on 21 patients with intracranial germinoma and treated with radiotherapy (RT) to the central nervous system at The University of Texas M. D.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Cranial Irradiation. Germinoma / radiotherapy. Spinal Cord / pathology. Spinal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Disease-Free Survival. Female. Humans. Male. Neoplasm Recurrence, Local. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate. Treatment Failure


30. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD: MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood; 2009 Oct 22;114(17):3533-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases of MYC+ DLBCL also had a higher risk of central nervous system relapse (P = .023), independent of other risk factors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / genetics. Prednisone / administration & dosage. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Young Adult


31. Park BB, Kim JG, Sohn SK, Kang HJ, Lee SS, Eom HS, Kwon HC, Oh SY, Kang JH, Oh SJ, Shin HJ, Suh C, Kim JH, Kim HY, Kim K, Ryoo BY, Kim WS: Consideration of aggressive therapeutic strategies for primary testicular lymphoma. Am J Hematol; 2007 Sep;82(9):840-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent site (44%) was in the CNS.
  • In conclusion, orchiectomy followed by intensive chemotherapy and IFRT including prophylaxis to the CNS and contralateral testis, should be considered as initial treatment in primary testicular lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma / drug therapy. Testicular Neoplasms / radiotherapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Central Nervous System Neoplasms / secondary. Combined Modality Therapy. Cranial Irradiation. Disease Progression. Disease-Free Survival. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Orchiectomy. Prognosis. Retrospective Studies. Time Factors. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17563078.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Ivanov P, Chernov M, Hayashi M, Nakaya K, Izawa M, Murata N, Kubo O, Ujiie H, Muragaki Y, Nakamura R, Iseki H, Hori T, Takakura K: Low-dose gamma knife radiosurgery for cavernous sinus hemangioma: report of 3 cases and literature review. Minim Invasive Neurosurg; 2008 Jun;51(3):140-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total microsurgical removal of these neoplasms may be extremely difficult due to their rich vascularization.
  • In all cases significant shrinkage of the neoplasm was marked at 3 months after treatment.
  • In all patients the shrinkage of the neoplasm was accompanied by notable improvement of the preexistent oculomotor nerve palsy.
  • [MeSH-major] Brain Neoplasms / surgery. Cavernous Sinus / surgery. Hemangioma, Cavernous, Central Nervous System / surgery. Neuronavigation. Radiosurgery
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging, Interventional. Male. Microsurgery. Middle Aged. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Tomography, X-Ray Computed


33. Crabtree KL, Arnold PM: Spinal seeding of a pilocytic astrocytoma in an adult, initially diagnosed 18 years previously. Pediatr Neurosurg; 2010;46(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal seeding of a pilocytic astrocytoma in an adult, initially diagnosed 18 years previously.
  • PA is the most common central nervous system glioma in the pediatric population and is rare in adults.
  • To our knowledge, this is the longest time reported from initial tumor resection of leptomeningeal dissemination to the distal spinal cord.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Meningeal Neoplasms / secondary. Neoplasm Seeding. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Biopsy. Child. Follow-Up Studies. Humans. Laminectomy. Lumbar Vertebrae. Magnetic Resonance Imaging. Male. Thoracic Vertebrae. Time Factors

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20516744.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


34. Sanna G, Franceschelli L, Rotmensz N, Botteri E, Adamoli L, Marenghi C, Munzone E, Cossu Rocca M, Verri E, Minchella I, Medici M, Catania C, Magni E, Goldhirsch A, Nolè F: Brain metastases in patients with advanced breast cancer. Anticancer Res; 2007 Jul-Aug;27(4C):2865-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a case control study to define current features of breast cancer related to central nervous system (CNS) metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Case-Control Studies. Cell Growth Processes / physiology. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis


35. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol; 2010 Mar;34(3):327-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
  • B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as "double-hit" lymphomas (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, and a spectrum of pathologic features overlapping with Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B-lymphoblastic lymphoma/leukemia (B-LBL).
  • The clinical and pathologic spectrum of this rare entity, including comparison to other high-grade B-cell neoplasms, has not been well defined.
  • Extranodal disease was present in 17/20 (85%), bone marrow involvement in 10/17 (59%) and central nervous system (CNS) disease in 5/11 (45%).
  • Nineteen patients were treated with combination chemotherapy, of whom 18 received rituximab and 14 received CNS-directed therapy.
  • DHL is a high-grade B-cell neoplasm with a poor prognosis, resistance to multiagent chemotherapy, and clinical and pathologic features distinct from other high-grade B-cell neoplasms.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Terminology as Topic. Time Factors. Treatment Outcome. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):525-34 [10757399.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1960-6 [11069032.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):52-4 [11120335.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51 [11343778.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):610-3 [12708908.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):474-9 [15239399.001]
  • [Cites] Blood. 1983 Nov;62(5):1142-6 [6605167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70 [6334305.001]
  • [Cites] Am J Clin Pathol. 1986 May;85(5):636-40 [3486584.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] N Engl J Med. 1988 May 26;318(21):1373-8 [3285208.001]
  • [Cites] Oncogene. 1988 May;2(5):431-5 [3131717.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1454-9 [2509518.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Jul;2(2):147-58 [2278969.001]
  • [Cites] Oncogene. 1991 Jan;6(1):145-8 [1992441.001]
  • [Cites] Leukemia. 1991 Jan;5(1):83-7 [1999960.001]
  • [Cites] Leukemia. 1991 Jun;5(6):473-8 [1711639.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Ann Hematol. 1991 Nov;63(5):282-7 [1958753.001]
  • [Cites] Ann Hematol. 1992 Feb;64(2):101-4 [1554791.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leukemia. 1994 Apr;8(4):560-3 [8152251.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):87-94 [8019967.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):55-61 [9541684.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):414-23 [15852472.001]
  • [Cites] Hum Pathol. 2005 May;36(5):571-5 [15948125.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1490-6 [16224216.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2313-23 [16193090.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Nov;171(1):52-6 [17074591.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1061-4 [17182663.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Am J Clin Pathol. 2008 Jan;129(1):157-66 [18089500.001]
  • [Cites] Curr Protoc Hum Genet. 2007 Jan;Chapter 8:Unit 8.8 [18428417.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1593-607 [18753947.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):716-25 [19120369.001]
  • [Cites] Leukemia. 2009 Feb;23(2):225-34 [18923440.001]
  • [Cites] Leukemia. 2009 Apr;23(4):777-83 [19151788.001]
  • [Cites] Haematologica. 2009 Jul;94(7):935-43 [19535347.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • (PMID = 20118770.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R37 CA076404; United States / NIGMS NIH HHS / GM / T32 GM074897; United States / NIGMS NIH HHS / GM / T32 GM074897-07
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ NIHMS305320; NLM/ PMC3152212
  •  go-up   go-down


41. Fujita A, Tomita N, Fujita H, Motohashi K, Hyo R, Yamazaki E, Hattori M, Fujisawa S, Kanamori H, Ogawa K, Motomura S, Kodama F, Ishigatsubo Y: Features of primary extranodal lymphoma in Kanagawa, a human T-cell leukemia virus type 1 nonendemic area in Japan. Med Oncol; 2009;26(1):49-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary extranodal sites included the gastrointestinal tract (30.4%), Waldeyer's ring (17.8%), orbits (7.0%), soft tissue and subcutaneous tissue (5.2%), bone (4.6%), skin (4.3%), thyroid gland (4.3%), testis and prostate (3.3%), bone marrow (3.3%), nasal and paranasal cavities (2.6%), salivary glands (2.3%), lung and pleura (2.0%), breast (1.8%), central nervous system (1.0%), uterus and ovary (0.5%), and others (9.8%).
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Female. Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / virology. Humans. Japan. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / virology. Male. Middle Aged. Neoplasm Staging. Prevalence. Survival Rate. Tonsillar Neoplasms / epidemiology. Tonsillar Neoplasms / pathology. Tonsillar Neoplasms / virology

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 1:19-24 [8172811.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2797-804 [15728226.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5432s-5440s [1394149.001]
  • [Cites] Br J Haematol. 2004 Jan;124(2):151-9 [14687024.001]
  • [Cites] Eur J Cancer. 1991;27(10):1201-8 [1835586.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5425s-574s [1356618.001]
  • [Cites] Rinsho Ketsueki. 1999 Mar;40(3):188-91 [10222623.001]
  • [Cites] Leuk Lymphoma. 1998 May;29(5-6):585-93 [9643572.001]
  • [Cites] Br J Haematol. 1996 Aug;94(2):373-5 [8759899.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 2:41-4 [9209639.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1023-33 [10572599.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Aug;25(8):1203-10 [2767109.001]
  • (PMID = 18568429.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Jeanneret-Sozzi W, Taghian A, Epelbaum R, Poortmans P, Zwahlen D, Amsler B, Villette S, Belkacémi Y, Nguyen T, Scalliet P, Maingon P, Gutiérrez C, Gastelblum P, Krengli M, Raad RA, Ozsahin M, Mirimanoff RO: Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer; 2008;8:86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central nervous system (CNS) was the site of relapse in 12 (14%) cases.
  • Local control is excellent with RT or combined modality treatment but systemic relapses, including that in the CNS, occurs frequently.
  • [MeSH-major] Breast Neoplasms / therapy. Breast Neoplasms, Male / therapy. Lymphoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Mastectomy. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1999 Jun;26(3):357-64 [10375092.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):233-41 [17932394.001]
  • [Cites] Oncology. 2005;69(3):256-60 [16166814.001]
  • [Cites] Breast Cancer Res Treat. 2005 Oct;93(3):191-8 [16172797.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Arch Pathol Lab Med. 1999 Dec;123(12):1208-18 [10583925.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):334-6 [10955857.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):253-6 [11703318.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):6-13 [11815954.001]
  • [Cites] J Surg Oncol. 2002 May;80(1):19-25; discussion 26 [11967901.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):397-404 [12764549.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1173-8 [12916870.001]
  • [Cites] Jpn J Clin Oncol. 2003 Aug;33(8):399-403 [14523060.001]
  • [Cites] Ai Zheng. 2004 Aug;23(8):939-42 [15301719.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Br J Cancer. 1976 Dec;34(6):585-612 [795448.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Acta Pathol Jpn. 1984 Mar;34(2):361-73 [6741549.001]
  • [Cites] Ann Surg. 1987 Feb;205(2):144-50 [3545107.001]
  • [Cites] Br J Surg. 1987 Mar;74(3):214-6 [3567516.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):843-6 [2777674.001]
  • [Cites] Cancer. 1991 Mar 1;67(5):1359-69 [1991299.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):725-35 [1730123.001]
  • [Cites] Am Surg. 1992 Dec;58(12):792-6 [1456611.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):274-8 [8454272.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):574-87 [8333556.001]
  • [Cites] Am J Surg Pathol. 1994 Mar;18(3):288-95 [8116797.001]
  • [Cites] S Afr Med J. 1995 Feb;85(2):85-9 [7597540.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):376-80 [9708637.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):25-30 [17541937.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1147-8 [17650450.001]
  • [Cites] Clin Lymphoma. 2005 Jun;6(1):37-42 [15989705.001]
  • (PMID = 18380889.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2330152
  •  go-up   go-down


43. Raizer JJ, Koutcher JA, Abrey LE, Panageas KS, DeAngelis LM, Lis E, Xu S, Zakian KL: Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol; 2005 Jan;71(2):173-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is a highly aggressive tumor responsive to high-dose methotrexate based regimens.
  • MRSI correlated with tumor response or progression on MRI; in three patients MRSI suggested disease progression prior to changes on MRI.
  • CONCLUSION: MRSI and MRI correlate with tumor response or progression and may allow early detection of disease recurrence.
  • [MeSH-major] Aspartic Acid / analogs & derivatives. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / immunology. Immunocompetence. Lymphoma / diagnosis. Lymphoma / immunology. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Choline / metabolism. Creatine / metabolism. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Lactic Acid / metabolism. Lipid Metabolism. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Protons. Survival Analysis

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 Jan;21(1):84-93 [10669230.001]
  • [Cites] Radiology. 1993 Mar;186(3):745-52 [8430183.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):319-26; discussion 326-8 [10690720.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):292-8 [11981274.001]
  • [Cites] Anticancer Res. 1996 May-Jun;16(3B):1533-8 [8694522.001]
  • [Cites] Invest Radiol. 1997 May;32(5):288-96 [9140749.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] Radiology. 1995 Jan;194(1):271-6 [7997566.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1271-6 [11955739.001]
  • [Cites] Anticancer Res. 1996 May-Jun;16(3B):1485-9 [8694517.001]
  • [Cites] Can J Neurol Sci. 1998 Feb;25(1):13-22 [9532276.001]
  • [Cites] Magn Reson Med. 2003 Feb;49(2):223-32 [12541241.001]
  • [Cites] NMR Biomed. 2003 Feb;16(1):12-8 [12577293.001]
  • [Cites] Neurosci Lett. 2003 May 22;342(3):163-6 [12757890.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):117-23 [9974066.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):915-28 [11429219.001]
  • [Cites] J Neurooncol. 1990 Oct;9(2):177-81 [2262803.001]
  • [Cites] Neuroradiology. 2001 Feb;43(2):169-77 [11326567.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):449-58 [8609557.001]
  • [Cites] Anticancer Res. 1996 May-Jun;16(3B):1565-7 [8694527.001]
  • [Cites] Neurology. 2002 Nov 26;59(10):1557-62 [12451197.001]
  • [Cites] Curr Opin Oncol. 2000 May;12(3):199-204 [10841191.001]
  • [Cites] Science. 1982 Jun 18;216(4552):1325-7 [7079765.001]
  • [Cites] Radiology. 1995 Dec;197(3):649-54 [7480733.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):525-34 [9322843.001]
  • [Cites] NMR Biomed. 1999 Nov;12(7):413-39 [10654290.001]
  • [Cites] Magn Reson Med. 1990 Oct;16(1):1-8 [2255232.001]
  • [Cites] NMR Biomed. 2002 Oct;15(6):385-92 [12357552.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):306-18 [10690719.001]
  • [Cites] Radiology. 1995 Nov;197(2):525-31 [7480706.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4):912-9; discussion 919-20 [12234397.001]
  • [Cites] Radiology. 1992 Dec;185(3):675-86 [1438744.001]
  • [Cites] Nat Med. 1996 Mar;2(3):323-5 [8612232.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] J Neurooncol. 1993 Jul;17(1):27-35 [8120569.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 Apr;64(4):516-23 [9576546.001]
  • [Cites] Radiology. 1987 Oct;165(1):215-9 [3628774.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65 [10782774.001]
  • [Cites] Neuroradiology. 2000 Oct;42(10):738-41 [11110076.001]
  • (PMID = 15690135.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Protons; 30KYC7MIAI / Aspartic Acid; 33X04XA5AT / Lactic Acid; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


44. Villafañe MF, Trione N, Corti M, Mendez N, Gancedo E, Zamora N, Levin M: Primary liver AIDS-related lympoma. Rev Inst Med Trop Sao Paulo; 2006 Jul-Aug;48(4):229-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of NHL associated with AIDS involves extranodal sites, especially the digestive tract and the central nervous system.
  • Primary liver lymphoma (PLL) is an uncommon neoplasm among these patients.
  • [MeSH-major] Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119682.001).
  • [ISSN] 0036-4665
  • [Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo
  • [ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


45. Ogino H, Shibamoto Y, Takanaka T, Suzuki K, Ishihara S, Yamada T, Sugie C, Nomoto Y, Mimura M: CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):803-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome.
  • PURPOSE: The prognostic significance of human chorionic gonadotropin (HCG) level in central nervous system germinoma remains controversial.
  • METHODS AND MATERIALS: We undertook a multi-institutional retrospective analysis of 103 patients with central nervous system germinoma whose serum HCG and/or beta-HCG level had been measured before treatment between 1984 and 2002.
  • The proportion of HCG-producing tumors was higher in the lesions at the basal ganglia than in the lesions at the other sites.
  • No correlation was found between tumor size and HCG level, but there seemed to be a weak correlation between size and beta-HCG.
  • Also, no other patient-, tumor-, or treatment-related factors seemed to influence the prognosis of the patients.
  • Relationship between tumor size and site and HCG level should be investigated further.
  • [MeSH-major] Central Nervous System Neoplasms / blood. Chorionic Gonadotropin / blood. Germinoma / blood. Neoplasm Proteins / blood
  • [MeSH-minor] Adolescent. Adult. Chorionic Gonadotropin, beta Subunit, Human / blood. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936563.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Neoplasm Proteins
  •  go-up   go-down


46. Arpino L, Vitiello V: Mid-occipital localization of extra-intracranial hemangiopericytoma. ANZ J Surg; 2009 Sep;79(9):664-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Hemangiopericytoma / therapy
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895536.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  •  go-up   go-down


47. Bayindir C, Mete O, Bilgic B: Retrospective study of 23 pathologically proven cases of central nervous system tuberculomas. Clin Neurol Neurosurg; 2006 Jun;108(4):353-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study of 23 pathologically proven cases of central nervous system tuberculomas.
  • INTRODUCTION: Extrapulmonary manifestations of tuberculosis involving the central nervous system (CNS) due to haematogenous spread are not a rare entity.
  • Tuberculoma is a granulomatous inflammatory process mimicking a neoplasm radiologically, so usually a biopsy is performed.
  • Histopathologic examination revealed granulomatous inflammation with central caseous necrosis in all patients.
  • DISCUSSION: Diagnosis of tuberculoma can be difficult, and in most of our cases, the clinical diagnosis was 'neoplasm'.
  • For this reason, clinicians must always be aware of it and consider it in the differential diagnosis of central nervous system mass lesions.
  • [MeSH-minor] Adolescent. Adult. Aged. Amphotericin B / therapeutic use. Anti-Infective Agents / therapeutic use. Child. Child, Preschool. Diagnosis, Differential. Female. Fever / diagnosis. Fever / epidemiology. Headache / diagnosis. Headache / epidemiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Necrosis / pathology. Retrospective Studies. Socioeconomic Factors

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Meningitis.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644403.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


48. Oltra S, Martinez F, Orellana C, Grau E, Fernandez JM, Cañete A, Castel V: The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma. Diagn Mol Pathol; 2005 Mar;14(1):53-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DCX specifically appears in migrating neurons of the central and peripheral nervous system and interacts with and regulates the microtobule cytoskeleton.
  • We have studied this gene by real-time quantitative RT-PCR in a total of 47 primary tumors and 202 samples of bone marrow or peripheral blood from 34 high-risk neuroblastoma patients as well as in 41 normal controls.
  • We conclude that DCX would be a more efficient marker of minimal disease in neuroblastoma and perhaps other tumors of neuronal lineage.
  • [MeSH-major] Biomarkers, Tumor / genetics. Microtubule-Associated Proteins / genetics. Neoplasm, Residual / diagnosis. Neoplasm, Residual / genetics. Neuroblastoma / diagnosis. Neuroblastoma / genetics. Neuropeptides / genetics
  • [MeSH-minor] Adult. Case-Control Studies. Child. Gene Expression. Humans. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Tyrosine 3-Monooxygenase / genetics

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714065.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Microtubule-Associated Proteins; 0 / Neuropeptides; 0 / doublecortin protein; EC 1.14.16.2 / Tyrosine 3-Monooxygenase
  •  go-up   go-down


49. Burghaus S, Hölsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blümcke I, Buslei R: A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch; 2010 Mar;456(3):287-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas.
  • Craniopharyngiomas (CP) are benign epithelial tumors of the sellar region and can be clinicopathologically distinguished into adamantinomatous (adaCP) and papillary (papCP) variants.
  • Herein, we characterized the cellular interface between the tumor and the surrounding brain tissue in 48 CP (41 adaCP and seven papCP) compared to non-neuroepithelial tumors, i.e., 12 cavernous hemangiomas, 10 meningiomas, and 14 metastases using antibodies directed against glial fibrillary acid protein (GFAP), vimentin, nestin, microtubule-associated protein 2 (MAP2) splice variants, and tenascin-C.
  • Furthermore, the outer tumor cell layer of adaCP showed a distinct expression of MAP2, a novel finding helpful in the differential diagnosis of epithelial tumors in the sellar region.
  • Our data support the hypothesis that adaCP, unlike other non-neuroepithelial tumors of the central nervous system, create a tumor-specific cellular environment at the tumor-brain junction.
  • Whether this facilitates the characteristic infiltrative growth pattern or is the consequence of an activated Wnt signaling pathway, detectable in 90% of these tumors, will need further consideration.
  • [MeSH-major] Craniopharyngioma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Brain / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Nerve Tissue Proteins / metabolism. Nestin. Tenascin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1595-603 [17122517.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Dec;28(6):480-8 [12445164.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Pathol. 2004 Jul;203(3):814-21 [15221941.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):675-87 [17492931.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):778-84 [11533656.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1213-26 [19002375.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8200-4 [16091738.001]
  • [Cites] Glia. 2000 Feb 1;29(3):233-45 [10642750.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3897-904 [8033113.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Nov 15;139(1):9-17 [12414089.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2531-7 [10582615.001]
  • [Cites] Glia. 1997 Jan;19(1):35-46 [8989566.001]
  • [Cites] J Biol Chem. 1990 Nov 15;265(32):19679-84 [2174050.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):763-76 [15792515.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Feb 21;65(2):259-67 [1373996.001]
  • [Cites] Acta Neuropathol. 1978 Sep 15;43(3):191-203 [696237.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):357-64 [18540944.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Jul 24;68(1):111-23 [1521317.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10894-8 [7479905.001]
  • [Cites] J Cell Sci. 1994 Nov;107 ( Pt 11):3115-25 [7699010.001]
  • [Cites] Cell Tissue Res. 2003 Dec;314(3):315-24 [14523640.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Matrix Biol. 2001 Feb;20(1):13-22 [11246000.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):155-70 [3292716.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):557-67 [15817911.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] Horm Res. 2008;69(4):193-202 [18204266.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):85-92 [15723616.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(17):6006-9 [3898077.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] Glia. 1995 Apr;13(4):233-54 [7615335.001]
  • [Cites] Dev Dyn. 2004 May;230(1):1-11 [15108304.001]
  • [Cites] Brain Tumor Pathol. 2005;22(2):75-8 [18095108.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1863-72 [16262626.001]
  • [Cites] Pituitary. 2005;8(2):75-9 [16195780.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Acta Neuropathol. 2007 May;113(5):585-90 [17221204.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):87-92 [11947939.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • [Cites] Eur J Endocrinol. 2008 Dec;159 Suppl 1:S95-9 [18775978.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:453-4 [16700324.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):1-9 [17319278.001]
  • (PMID = 20069432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Microtubule-Associated Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tenascin; 0 / Vimentin
  •  go-up   go-down


50. Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, Tohnya T, Figg WD, Royce C: A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res; 2007 Dec 1;13(23):7101-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
  • PURPOSE: Inhibition of angiogenesis represents a promising new therapeutic strategy for treating primary malignant brain tumors.
  • Lenalidomide, a potent analogue of the antiangiogenic agent thalidomide, has shown significant activity in several hematologic malignancies, and therefore we chose to explore its tolerability and activity in patients with primary central nervous system tumors.
  • EXPERIMENTAL DESIGN: A phase I interpatient dose escalation trial of lenalidomide in patients with recurrent primary central nervous system tumors was conducted.
  • In the group of 24 patients with recurrent glioblastoma, the median time to tumor progression was <2 months and only 12.5% of patients were progression-free at 6 months.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Central Nervous System Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056189.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  •  go-up   go-down


51. Avilés A, Delgado S, Nambo MJ, Neri N, Murillo E, Cleto S: Primary breast lymphoma: results of a controlled clinical trial. Oncology; 2005;69(3):256-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common site of relapse was the central nervous system.
  • Until now, no second neoplasm or acute leukemia has been observed.
  • Prophylaxis to the central nervous system will be considered in the initial treatment to improve outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Lymphoma / drug therapy. Lymphoma / radiotherapy
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16166814.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Controlled Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


52. Rebischung C, Hoffmann D, Stefani L, Desruet MD, Wang K, Adelstein SJ, Artignan X, Vincent F, Gauchez AS, Zhang H, Fagret D, Vuillez J, Kassis AI, Balosso J: First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX plus (125)IUdR. Int J Radiat Biol; 2008 Dec;84(12):1123-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When 5-iodo-2'-deoxyuridine labeled with (125)I ((125)IUdR) is incorporated into the DNA of mitotic tumor cells, the Auger electrons emitted during iodine decay are highly cytotoxic.
  • The radiotherapeutic efficacy of (125)IUdR administered intrathecally has also been established in animals bearing spinal cord tumors, and MTX is known to potentiate the response.
  • There was no evidence of local central nervous system toxicity.
  • Three months later, neoplastic meningitis recurred and meningeal tumor infiltration was observed on magnetic resonance imaging.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Idoxuridine / therapeutic use. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / radiotherapy. Methotrexate / therapeutic use. Radiopharmaceuticals / therapeutic use
  • [MeSH-minor] Adult. Antigens, Tumor-Associated, Carbohydrate / cerebrospinal fluid. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Combined Modality Therapy. Drug Resistance, Neoplasm. Fatal Outcome. Female. Humans. Injections, Spinal. Iodine Radioisotopes. Neoplasm Recurrence, Local. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology

  • Hazardous Substances Data Bank. IDOXURIDINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061137.001).
  • [ISSN] 0955-3002
  • [Journal-full-title] International journal of radiation biology
  • [ISO-abbreviation] Int. J. Radiat. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; LGP81V5245 / Idoxuridine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


53. Kitai R, Horita R, Sato K, Yoshida K, Arishima H, Higashino Y, Hashimoto N, Takeuchi H, Kubota T, Kikuta K: Nestin expression in astrocytic tumors delineates tumor infiltration. Brain Tumor Pathol; 2010 Apr;27(1):17-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in astrocytic tumors delineates tumor infiltration.
  • Nestin is an intermediate filament protein expressed in undifferentiated cells during central nervous system development, and glioma is known to be a highly infiltrative tumor.
  • We determined whether nestin was expressed in astrocytic tumors and could identify infiltrating tumor cells.
  • We screened 65 archival, paraffin-embedded adult astrocytic tumors using immunohistochemical staining and computerized overlaid photographs.
  • Normal biopsied brains and metastatic brain tumors were also examined.
  • The intensity of nestin expression corresponded to the tumor grade.
  • Overlaid images showed that nestin immunostaining delineated tumor invasion into adjacent gray and white matter.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Intermediate Filament Proteins / metabolism. Intermediate Filament Proteins / physiology. Nerve Tissue Proteins / metabolism. Nerve Tissue Proteins / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Child. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Nestin. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425043.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


54. Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, Niitsu N, Miwa H, Asaoku H, Kosugi H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Yamamoto K, Yamaguchi M, Nakamura S, Naoe T, Kinoshita T, IVL Study Group in Japan: Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci; 2010 Jun;101(6):1480-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.
  • Intravascular large B-cell lymphoma (IVLBCL) is a rare disease entity with a high incidence of central nervous system (CNS) involvement at diagnosis.
  • To evaluate CNS involvement, particularly recurrence including progression on therapy and relapse of IVLBCL, we retrospectively analyzed 109 patients with IVLBCL receiving chemotherapies with or without rituximab.
  • In 82 patients (75%) without CNS involvement at initial diagnosis, risk of CNS recurrence at 3 years was 25% with a median follow-up in survivors of 39 months (range, 2-158 months).
  • In 27 patients (25%) with CNS involvement at initial diagnosis, risk of CNS recurrence at 1 year was 25% with a median follow-up in survivors of 18 months (range, 10-77 months).
  • Duration from diagnosis to CNS recurrence tended to be short in patients with CNS involvement at diagnosis.
  • No significant difference in risk of CNS recurrence was found between patients receiving chemotherapies with or without rituximab.
  • On multivariate analysis skin involvement at initial diagnosis was identified as a predictive factor for CNS recurrence in patients without CNS involvement at diagnosis (hazard ratio, 5.27; 95% confidence interval, 1.59-17.4; P = 0.007).
  • Survival rate after CNS recurrence at 2 years was 12% in patients without CNS involvement at diagnosis.
  • Central nervous system recurrence is a serious complication in IVLBCL patients and optimal strategies for CNS involvement should be established to obtain further improvements to clinical outcomes in the rituximab era.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Retrospective Studies. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20412122.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


55. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss D, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine P, Medina LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Complications of craniofacial resection for malignant tumors of the skull base: report of an International Collaborative Study. Head Neck; 2005 Jun;27(6):445-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of craniofacial resection for malignant tumors of the skull base: report of an International Collaborative Study.
  • BACKGROUND: Advances in imaging, surgical technique, and perioperative care have made craniofacial resection (CFR) an effective and safe option for treating malignant tumors involving the skull base.
  • Because of the relative rarity of these tumors, most existing data on postoperative complications come from individual reports of relatively small series of patients.
  • This international collaborative report examines a large cohort of patients accumulated from multiple institutions with the aim of identifying patient-related and tumor-related predictors of postoperative morbidity and mortality and set a benchmark for future studies.
  • Postoperative complications were classified into systemic, wound, central nervous system (CNS), and orbit.
  • Wound complications occurred in 237 (19.8%), CNS-related complications in 193 (16.2%), orbital complications in 20 (1.7%), and systemic complications in 57 (4.8%) patients.
  • CONCLUSIONS: CFR is a safe surgical treatment for malignant tumors of the skull base, with an overall mortality of 4.7% and complication rate of 36.3%.
  • The impact of medical comorbidity and intracranial tumor extent should be carefully considered when planning therapy for patients whose tumors are amenable to CFR.
  • [MeSH-major] Postoperative Complications. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. International Cooperation. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 15825205.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


56. Kułakowska A, Pogorzelski R, Drozdowski W: [Primary central nervous system lymphoma with initial symptoms suggesting herpes encephalitis]. Pol Merkur Lekarski; 2008 Jan;24(139):30-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary central nervous system lymphoma with initial symptoms suggesting herpes encephalitis].
  • Primary central nervous system lymphoma (PCNSL) is rare neoplasm, affecting both immunocompetent and immunodeficient patients.
  • It is usually seen as intracranial tumor, but it can often involve cerebrospinal meninges, eyeballs and spinal cord.
  • We described a case of 43 year old patient with diagnosed PCNSL and discussed clinical signs, diagnostics and treatment of the neoplasm.
  • [MeSH-major] Brain Neoplasms / diagnosis. Encephalitis, Herpes Simplex / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634249.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


57. Furuse M, Miyatake SI, Kuroiwa T: Cavernous malformation after radiation therapy for astrocytoma in adult patients: report of 2 cases. Acta Neurochir (Wien); 2005 Oct;147(10):1097-101; discussion 1101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cavernous malformation after radiation therapy for astrocytoma in adult patients: report of 2 cases.
  • We describe two adult patients with cavernous malformation after irradiation for astrocytoma.
  • Radiation-induced cavernous malformations are rare in adult patients with astrocytoma.
  • [MeSH-major] Astrocytoma / radiotherapy. Blood Vessels / pathology. Blood Vessels / radiation effects. Brain Neoplasms / radiotherapy. Hemangioma, Cavernous, Central Nervous System / etiology. Neoplasms, Radiation-Induced / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / radiotherapy. Dementia / diagnosis. Dementia / etiology. Dementia / physiopathology. Frontal Lobe / blood supply. Frontal Lobe / pathology. Frontal Lobe / radiation effects. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Temporal Lobe / blood supply. Temporal Lobe / pathology. Temporal Lobe / radiation effects. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16021386.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


58. Pfister C, Ritz R, Endemann E, Schittenhelm J, Bornemann A, Tatagiba MS, Roser F: Evidence of ubiquitous in vivo and in vitro expression of pro-apoptotic Smac/DIABLO protein in meningioma cell lines. Oncol Rep; 2009 May;21(5):1181-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although meningiomas are one of the most common tumors in the central nervous system, the adjuvant treatment for recurrent or malignant meningiomas is not satisfactory.
  • Changes in apoptosis mechanisms play important roles in tumor pathogenesis.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Mitochondrial Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / genetics. Male. Middle Aged. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19360292.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / RNA, Neoplasm
  •  go-up   go-down


59. Gläsker S, Berlis A, Pagenstecher A, Vougioukas VI, Van Velthoven V: Characterization of hemangioblastomas of spinal nerves. Neurosurgery; 2005 Mar;56(3):503-9; discussion 503-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Hemangioblastoma is classified as a benign tumor of the central nervous system.
  • Peripheral nervous system hemangioblastomas to date have been described only in a few case reports.
  • These tumors occurred in 2% of all patients with hemangioblastomas of the central nervous system, or 6% of all patients with spinal hemangioblastomas.
  • Radiographically, the tumors easily could be mistaken for schwannomas or metastases; however, they did have some typical features.
  • Most of the tumors arose from the dorsal sensory fascicles.
  • CONCLUSION: These tumors harbor diagnostic and therapeutic pitfalls.
  • In general, the tumors are surgically more challenging, and clinically significant bleeding as well as local tumor recurrence is more common than in intradural hemangioblastomas, mostly because of the frequency of incorrect initial radiographic diagnosis.
  • We suggest that because of the surgical consequences, hemangioblastoma should always be considered to be an important radiological differential diagnosis for nerve sheath tumors.
  • [MeSH-major] Hemangioblastoma / pathology. Hemangioma, Capillary / pathology. Peripheral Nervous System Neoplasms / pathology. Spinal Nerves / pathology
  • [MeSH-minor] Adult. Blood Loss, Surgical. Diagnosis, Differential. Female. Humans. Infratentorial Neoplasms / epidemiology. Infratentorial Neoplasms / pathology. Infratentorial Neoplasms / radiography. Infratentorial Neoplasms / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Neurilemmoma / diagnosis. Neuroma / diagnosis. Retrospective Studies. Treatment Outcome. von Hippel-Lindau Disease / epidemiology. von Hippel-Lindau Disease / pathology. von Hippel-Lindau Disease / radiography. von Hippel-Lindau Disease / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730575.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


60. Herrlinger U, Hebart H, Kanz L, Dichgans J, Weller M: Relapse of primary CNS lymphoma after more than 10 years in complete remission. J Neurol; 2005 Nov;252(11):1409-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of primary CNS lymphoma after more than 10 years in complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Humans. Male. Methotrexate / therapeutic use. Procarbazine / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Jul 1;102(1):324-7 [12649152.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):188-95 [8027800.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1745-53 [9164181.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4489-95 [14597744.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1356-9 [6616403.001]
  • [Cites] Neurology. 2000 Apr 25;54(8):1707-8 [10762527.001]
  • [Cites] Ann Hematol. 2003 Nov;82(11):712-3 [12961033.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):626-32 [14628129.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1789-93 [12685833.001]
  • (PMID = 15895304.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


61. Fukuda M: [Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia]. Rinsho Ketsueki; 2005 Nov;46(11):1223-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient also had severe mental retardation caused by a congenital central nervous system malformation.
  • [MeSH-minor] Administration, Oral. Adult. Humans. Male. Neoplasm Recurrence, Local. Remission Induction

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440808.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


62. Iczkowski KA, Butler SL, Shanks JH, Hossain D, Schall A, Meiers I, Zhou M, Torkko KC, Kim SJ, MacLennan GT: Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. Hum Pathol; 2008 Feb;39(2):275-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors.
  • Their reactivity is well characterized in testicular, but not extragonadal and metastatic, germ cell tumors.
  • A total of 93 germ cell tumors (41 seminoma, 22 embryonal carcinoma, 18 teratoma, and 12 yolk sac tumor) were obtained from the central nervous system (30), mediastinum (23), retroperitoneum/abdomen (31), and other locations (9).
  • Sensitivity and specificity were high for OCT3/4 discriminating seminoma and embryonal carcinoma, and c-kit discriminating seminoma, from other germ cell tumors.
  • Epithelial membrane antigen discriminated teratoma from other nonseminomas with a sensitivity of 1 but reacted occasionally in embryonal carcinoma (3/15) and yolk sac tumor (2/7).
  • [MeSH-major] Biomarkers, Tumor / analysis. Germinoma / chemistry. Neoplasm Proteins / analysis. Ovarian Neoplasms / chemistry. Testicular Neoplasms / chemistry
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / analysis. Antibodies, Monoclonal, Murine-Derived. Female. Fluorescent Antibody Technique, Indirect. Humans. Male. Octamer Transcription Factor-3 / analysis. Sensitivity and Specificity. Transcription Factor AP-2 / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Hum Pathol. 2013 Dec;44(12):2873
  • (PMID = 18045648.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / Transcription Factor AP-2; 0 / monoclonal antibody D2-40
  •  go-up   go-down


63. Robbens C, Vanwyck R, Wilms G, Sciot R, Debiec-Rychter M: An extrarenal rhabdoid tumor of the cervical spine with bony involvement. Skeletal Radiol; 2007 Apr;36(4):341-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An extrarenal rhabdoid tumor of the cervical spine with bony involvement.
  • A case of a histologically proven rhabdoid tumor of the cervical spine in a 19-year-old Caucasian male is presented.
  • Primary extrarenal rhabdoid tumors are very rare.
  • When the central nervous system is involved, the tumor usually is located in the brain.
  • Only three cases of primary spinal rhabdoid tumor have been reported.
  • This case is the first reported extradural rhabdoid tumor of the spinal canal and the first case of a rhabdoid tumor located in the spinal canal with bony involvement.
  • [MeSH-major] Bone Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Rhabdoid Tumor / diagnosis. Spinal Neoplasms / diagnosis. Thoracic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Angiography, Digital Subtraction / methods. Contrast Media / administration & dosage. Fatal Outcome. Follow-Up Studies. Gadolinium DTPA. Humans. Image Enhancement / methods. Magnetic Resonance Imaging / methods. Male. Radionuclide Imaging. Rare Diseases. Spine / diagnostic imaging. Spine / pathology. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Jul 15;52(2):290-6 [6861072.001]
  • [Cites] Clin Neuropathol. 1994 Jul-Aug;13(4):221-4 [7955669.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):1010-29 [8092393.001]
  • [Cites] Pediatr Radiol. 2001 Sep;31(9):631-3 [11512002.001]
  • [Cites] Pediatr Radiol. 2003 Apr;33(4):275-7 [12709762.001]
  • [Cites] Ann Diagn Pathol. 1998 Dec;2(6):351-62 [9930572.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1485-91 [15489652.001]
  • [Cites] Radiographics. 1999 Sep-Oct;19(5):1253-80 [10489179.001]
  • [Cites] Cancer. 1978 May;41(5):1937-48 [206343.001]
  • [Cites] Pediatr Neurosurg. 2000 Mar;32(3):145-9 [10867562.001]
  • [Cites] Pathol Res Pract. 1987 Oct;182(5):713-8 [2446296.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Mar;25(3):476-80 [15037475.001]
  • [Cites] Adv Anat Pathol. 2000 May;7(3):181-90 [10809224.001]
  • [Cites] Pediatr Neurosurg. 1994;21(4):232-6 [7865408.001]
  • [Cites] Spine (Phila Pa 1976). 1987 Jul-Aug;12 (6):620-4 [3660093.001]
  • [Cites] Neuroradiology. 1997 Oct;39(10):719-23 [9351109.001]
  • (PMID = 16602014.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


64. Darby S, Hancock BW: Localised non-Hodgkin lymphoma of the testis: the Sheffield Lymphoma Group experience. Int J Oncol; 2005 Apr;26(4):1093-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only 1 of these relapses was in the central nervous system; 1 in bone, 1 in skin, 2 in the contralateral testis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery. Neoplasm Recurrence, Local. Orchiectomy. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Combined Modality Therapy. Humans. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies


65. Cooper PB, Auerbach A, Aguilera NS, Adair C, Moores L, Geyer D, Rushing EJ: Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature. Clin Neuropathol; 2006 Sep-Oct;25(5):232-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature.
  • OBJECTIVE AND IMPORTANCE: Isolated anaplastic large cell lymphoma (ALCL) presenting in the primary central nervous system is distinctly uncommon.
  • The authors describe a case that clinically and radiographically simulated a primary glial neoplasm.
  • There appeared to be a clear demarcation between white matter and tumor with no obvious necrosis.
  • CONCLUSION: Reported in less than 20 patients, primary ALCL in an immunocompetent patient is rarely found intracranially; however, its ability to mimic glial neoplasms as well as other pathologies underlines its importance.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / analysis. Combined Modality Therapy. Diagnosis, Differential. Glioma / pathology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Radiotherapy. Seizures / etiology


66. Menon G, Easwer HV, Radhakrishnan VV, Nair S: Symptomatic granular cell tumour of the pituitary. Br J Neurosurg; 2008 Feb;22(1):126-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a 42-year-old male with a granular cell neoplasm of the sellar suprasellar region and attempt to discuss the controversies shrouding this distinct clinicopathological entity.
  • [MeSH-major] Adenoma / diagnosis. Central Nervous System Cysts / diagnosis. Granular Cell Tumor / diagnosis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Optic Atrophy / etiology. Pituitary Gland / pathology. Recovery of Function / physiology. Treatment Outcome. Visual Acuity / physiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952719.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Masucci GV, Månsson-Brahme E, Ragnarsson-Olding B, Nilsson B, Wagenius G, Hansson J: Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. Melanoma Res; 2006 Aug;16(4):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Temozolomide is a rapidly absorbed chemotherapeutic agent, achieving significant central nervous system penetration.
  • The primary objective was to determine the safety and tolerance of temozolomide administered orally 200 mg/m days 1-5, in sequential combination with subcutaneous injections of 4.5x10 IU recombinant human interleukin-2 on days 8-11, 15-18 and 22-25 in patients with measurable, progressive metastatic malignant melanoma without radiological signs of central nervous system metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Melanoma / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Female. Humans. Immunotherapy. Injections, Subcutaneous. Interleukin-2 / administration & dosage. Lymphatic Metastasis / immunology. Lymphatic Metastasis / pathology. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Skin Neoplasms / drug therapy. Skin Neoplasms / immunology. Skin Neoplasms / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845332.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


68. Jung SM, Kuo TT: Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma. Mod Pathol; 2005 Jun;18(6):788-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma.
  • The differential diagnosis between hemangioblastoma of the central nervous system and metastatic clear cell renal cell carcinoma can be problematic, because they may share striking morphologic similarities.
  • A total of 22 cases of cerebellar hemangioblastoma, five cases of metastatic clear cell renal cell carcinoma to the central nervous system, and 16 primary cases of clear cell renal cell carcinoma were studied with immunohistochemical staining of both CD10 and inhibin A.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / pathology. Central Nervous System Neoplasms / pathology. Hemangioblastoma / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Inhibins / analysis. Male. Middle Aged. Neoplasm Metastasis. Neprilysin / analysis


69. Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ: Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain; 2010 Aug;133(Pt 8):2232-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Taken together, the clinical analyses and laboratory findings support the interpretation that improvement in disability after alemtuzumab may result, in part, from neuroprotection associated with increased lymphocytic delivery of neurotrophins to the central nervous system.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Autoimmunity. Immunologic Factors / therapeutic use. Multiple Sclerosis, Relapsing-Remitting / drug therapy. Multiple Sclerosis, Relapsing-Remitting / immunology
  • [MeSH-minor] Adult. Animals. Antibodies, Monoclonal, Humanized. Cells, Cultured. Cross-Sectional Studies. Disability Evaluation. Female. Humans. Intercellular Signaling Peptides and Proteins / metabolism. Interferon beta-1a. Interferon-beta / therapeutic use. Longitudinal Studies. Lymphocytes / immunology. Male. Middle Aged. Neuroimmunomodulation / drug effects. Rats. Rats, Sprague-Dawley. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Interferon Beta-1a .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Brain. 2010 Aug;133(Pt 8):2182-4 [20826427.001]
  • (PMID = 20659956.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / 623; United Kingdom / Multiple Sclerosis Society / / 767
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Immunologic Factors; 0 / Intercellular Signaling Peptides and Proteins; 3A189DH42V / alemtuzumab; 77238-31-4 / Interferon-beta; XRO4566Q4R / Interferon beta-1a
  •  go-up   go-down


70. Pinto GR, Clara CA, Santos MJ, Almeida JR, Burbano RR, Rey JA, Casartelli C: Mutation analysis of gene PAX6 in human gliomas. Genet Mol Res; 2007;6(4):1019-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are the most common tumors of the central nervous system.
  • In spite of the marked advances in the characterization of the molecular pathogenesis of gliomas, these tumors remain incurable and, in most of the cases, resistant to treatments, due to their molecular heterogeneity.
  • Gene PAX6, which encodes a transcription factor that plays an important role in the development of the central nervous system, was recently recognized as a tumor suppressor in gliomas.
  • Therefore, we conclude that the tumor suppressor role of PAX6, reported in previous studies on gliomas, is not due to mutation in its coding and regulating regions, suggesting the involvement of epigenetic mechanisms in the silencing of PAX6 in these tumors.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Eye Proteins / genetics. Glioma / genetics. Homeodomain Proteins / genetics. Mutation. Paired Box Transcription Factors / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Base Sequence. Child. Child, Preschool. DNA Mutational Analysis. DNA Primers / genetics. DNA, Neoplasm / genetics. Ependymoma / genetics. Epigenesis, Genetic. Female. Gene Silencing. Humans. Infant. Male. Middle Aged. Oligodendroglioma / genetics. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273794.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Eye Proteins; 0 / Homeodomain Proteins; 0 / PAX6 protein; 0 / Paired Box Transcription Factors; 0 / Repressor Proteins
  •  go-up   go-down


71. Tumialán LM, Brat DJ, Fountain AJ, Barrow DL: An astroblastoma mimicking a cavernous malformation: case report. Neurosurgery; 2007 Mar;60(3):E569-70; discussion E570
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Astroblastomas are rare glial neoplasms that usually occur in young adults and have a predilection for the cerebral hemispheres.
  • Imaging studies reveal circumscribed, contrast-enhancing tumors that contain both cystic and solid components with variable peritumoral edema.
  • Hemorrhage, which suggested the presence of a vascular lesion in this patient, has not been previously described as a feature of this neoplasm.
  • The clinical, radiographic, and pathological features of astroblastomas, as well as the natural history of these rare glial neoplasms, are reviewed.
  • This case illustrates the capacity of astroblastomas to hemorrhage, disguising the classic radiographic findings typical of this glial neoplasm.
  • [MeSH-major] Brain Neoplasms / radiography. Brain Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / radiography. Hematoma, Epidural, Cranial / radiography. Hematoma, Epidural, Cranial / surgery. Neoplasms, Neuroepithelial / radiography. Neoplasms, Neuroepithelial / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Astroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327764.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Pestalozzi BC, Francis P, Quinaux E, Dolci S, Azambuja E, Gelber RD, Viale G, Balil A, Andersson M, Nordenskjöld B, Gnant M, Gutierrez J, Láng I, Crown JP, Piccart-Gebhart M, BIG 02-98 Collaborative Group: Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Ann Oncol; 2008 Nov;19(11):1837-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.
  • BACKGROUND: Breast cancer central nervous system (CNS) metastases are an increasingly important problem because of high CNS relapse rates in patients treated with trastuzumab and/or taxanes.
  • After a median follow-up of 5 years, 403 patients had died and detailed information on CNS relapse was collected for these patients.
  • RESULTS: CNS relapse occurred in 4.0% of control patients and 3.7% of docetaxel-treated patients.
  • CNS relapse occurred in 27% of deceased patients in both treatment groups.
  • CNS relapse was usually accompanied by neurologic symptoms (90%), and 25% of patients with CNS relapse died without evidence of extra-CNS relapse.
  • Only 20% of patients survived 1 year from the diagnosis of CNS relapse.
  • Prognosis of CNS relapse was worse for patients with meningeal carcinomatosis when compared with brain metastases.
  • CONCLUSION: There is no evidence that adjuvant docetaxel treatment is associated with an increased frequency of CNS relapse.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2006 Jun;17(6):935-44 [16603601.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1133-44 [17675394.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):121-33 [18182617.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2349-51 [10829059.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):353-6 [11332148.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1772-7 [16150805.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1760-6 [15386311.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):232-6 [8625097.001]
  • [Cites] Breast Cancer Res Treat. 2004 Dec;88(3):273-80 [15609130.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):44-55 [15630443.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):2972-7 [12784331.001]
  • (PMID = 18562328.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-73362
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2733076
  •  go-up   go-down


73. Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, Schuller JC, Pedroni E, Goitein G: Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys; 2009 Nov 15;75(4):1111-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brainstem compression at the time of PT (p = 0.007) and gross tumor volume >25 mL (p = 0.03) were associated with lower LC rates.
  • High-grade late toxicity consisted of one patient with Grade 3 and one patient with Grade 4 unilateral optic neuropathy, and two patients with Grade 3 central nervous system necrosis.
  • With target definition, dose prescription and normal organ tolerance levels similar to passive-scattering based PT series, complication-free, tumor control and survival rates are at present comparable.
  • [MeSH-major] Chondrosarcoma / radiotherapy. Chordoma / radiotherapy. Protons / therapeutic use. Skull Base Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Child. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm, Residual. Radiotherapy Dosage. Relative Biological Effectiveness. Survival Rate. Tumor Burden. Young Adult

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19386442.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


74. Kao CL, Chiou SH, Ho DM, Chen YJ, Liu RS, Lo CW, Tsai FT, Lin CH, Ku HH, Yu SM, Wong TT: Elevation of plasma and cerebrospinal fluid osteopontin levels in patients with atypical teratoid/rhabdoid tumor. Am J Clin Pathol; 2005 Feb;123(2):297-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of plasma and cerebrospinal fluid osteopontin levels in patients with atypical teratoid/rhabdoid tumor.
  • Osteopontin, a cancer metastasis-associated gene, is specifically up-regulated in central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT), but its biological behavior in the progression of CNS AT/RT has never been studied.
  • The differences in osteopontin expression in plasma, CSF, and tumor samples in AT/RT and medulloblastoma correlated with survival differences.
  • [MeSH-major] Brain Neoplasms / metabolism. Rhabdoid Tumor / metabolism. Sialoglycoproteins. Teratoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Humans. Infant. Infant, Newborn. Medulloblastoma / metabolism. Medulloblastoma / mortality. Medulloblastoma / pathology. Neoplasm Recurrence, Local. Osteopontin. Survival Rate

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842057.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


75. Fèvre-Montange M, Grand S, Champier J, Hoffmann D, Pasquier B, Jouvet A: Bcl-2 expression in a papillary tumor of the pineal region. Neuropathology; 2008 Dec;28(6):660-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 expression in a papillary tumor of the pineal region.
  • Neuroepithelial papillary tumor of the pineal region (PTPR) has been described by several groups and recognized by the 2007 World Health Organization Classification of Tumors of the Central Nervous System.
  • It may also be involved in neuroendocrine differentiation in some tumors.
  • This intense expression of Bcl-2 in one case of PTPR with a high proliferation index (8%) might be related to the malignancy of this neoplasm.
  • [MeSH-major] Brain Neoplasms / metabolism. Neoplasms, Neuroepithelial / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Adult. Basal Ganglia / pathology. Biopsy. Cerebral Cortex / pathology. Cytoplasm / metabolism. Epithalamus / pathology. Female. Hippocampus / pathology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Pineal Gland

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410278.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


76. Frobisher C, Lancashire ER, Reulen RC, Winter DL, Stevens MC, Hawkins MM, British Childhood Cancer Survivor Study: Extent of alcohol consumption among adult survivors of childhood cancer: the British Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev; 2010 May;19(5):1174-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of alcohol consumption among adult survivors of childhood cancer: the British Childhood Cancer Survivor Study.
  • Survivors of a central nervous system neoplasm or leukemia, particularly those treated with brain irradiation, were the least likely to have adverse drinking behaviors when compared with the general population.
  • However, survivors of Hodgkin's lymphoma, non-Hodgkin's lymphoma, Wilms' tumor, bone sarcoma, and soft tissue sarcoma had adverse drinking behaviors at levels expected from the general population.
  • [MeSH-major] Alcohol Drinking / epidemiology. Neoplasms / epidemiology. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Risk Factors. Surveys and Questionnaires. Young Adult

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Alcohol.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR
  • (PMID = 20447915.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Easton D; Hawkins M; Jenkinson H; Jenney M; Lancashire E; Pritchard-Jones K; Stevens M; Stiller C; Sugden E; Toogood A; Wallace H
  •  go-up   go-down


77. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss DM, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine PA, Medina dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study. Arch Otolaryngol Head Neck Surg; 2006 Jan;132(1):73-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SETTING: Seventeen international tertiary referral centers performing craniofacial surgery for malignant skull base tumors.
  • PATIENTS: A total of 53 patients were identified from a database of 1307 patients who had craniofacial resection for malignant tumors at 17 institutions.
  • Complications were classified into overall, local, central nervous system, systemic, and orbital.
  • Local wound complications occurred in 6 patients (11%), central nervous system in 7 (13%), systemic in 3 (6%), and orbital in 1 (2%).
  • CONCLUSIONS: Craniofacial resection in patients with malignant melanoma of the skull base has mortality (6%) and complication rates (26%) comparable to other malignant tumors of the skull base.
  • [MeSH-major] Cranial Fossa, Anterior / surgery. Facial Bones / surgery. Melanoma / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. International Cooperation. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415433.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Nichols GL, Jacobson CA, Ferman D, Lichtman SM: Unusual uterine recurrence of primary central nervous system lymphoma. Clin Adv Hematol Oncol; 2006 Sep;4(9):697-8, discussion 699-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual uterine recurrence of primary central nervous system lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Central Nervous System Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Uterine Neoplasms / secondary. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Disease Progression. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging / methods. Positron-Emission Tomography / methods. Sensitivity and Specificity. Stem Cell Transplantation. Tomography, Emission-Computed / methods

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17099627.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Gill S, Herbert KE, Prince HM, Wolf MM, Wirth A, Ryan G, Carney DA, Ritchie DS, Davies JM, Seymour JF: Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol; 2009 Oct;147(1):83-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.
  • Reported rates of central nervous system (CNS) involvement in mantle cell lymphoma (MCL) are highly variable but substantial (4-26%).
  • Data is lacking regarding risk factors for CNS relapse, and for those patients in whom CNS prophylaxis could be beneficial.
  • We present single institution retrospective analysis of data of baseline features, clinical course, rate of CNS disease and putative risk factors in 62 patients with MCL (18 female, 44 male).
  • CNS disease (all cases were symptomatic) occurred in four patients at a median of 12 months (range 1-58) from diagnosis, with a crude incidence of 6.5% and 5-year actuarial incidence of 5 +/- 3%.
  • Survival after CNS relapse ranged from 2-9 months.
  • Patients who developed CNS disease had a significantly shorter survival from diagnosis than those who did not (P = 0.0024).
  • Symptomatic CNS disease in patients with MCL either at presentation or relapse is an uncommon but devastating complication.
  • In younger patients, more aggressive immuno-chemotherapy regimens containing CNS-penetrating agents may reduce the incidence of CNS disease.
  • While not routinely justified for all patients, CNS prophylaxis may particularly benefit patients with blastic histology at diagnosis, or those with systemic relapse after first-line treatment.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Recurrence. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694718.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, Stamattoulas A, Dupriez B, Raphaël M, Pico JL, Ribrag V, GELA, GOELAMS: Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol; 2005 Dec;16(12):1928-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia.
  • PATIENTS AND METHODS: Treatment began with a prephase (low-dose steroids, vincristine and cyclophosphamide), except in patients with low tumor burden.
  • Group C (patients with central nervous system and/or bone marrow involvement with < 30% of blast cells) received eight courses containing intensified high-dose methotrexate, high-dose cytarabine, etoposide and triple IT injections.
  • CONCLUSION: Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284057.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


81. Al-Hussaini M, Hirschowitz L, McCluggage WG: Uterine neoplasms composed of rhabdoid cells do not exhibit loss of INI1 immunoreactivity and are not related to childhood malignant rhabdoid tumor. Int J Gynecol Pathol; 2008 Apr;27(2):236-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine neoplasms composed of rhabdoid cells do not exhibit loss of INI1 immunoreactivity and are not related to childhood malignant rhabdoid tumor.
  • Malignant rhabdoid tumors are rare childhood neoplasms which occur most commonly in the kidneys, soft tissue, and central nervous system.
  • Recently, it has been demonstrated that malignant rhabdoid tumors in childhood are characterized by biallelic deletion or mutation involving the SMARCB1/INI1 gene on chromosome 22.
  • Neoplasms with a similar morphology occur in adults, either in pure form or associated with a parent tumor.
  • It is controversial whether such neoplasms in adults are related to childhood malignant rhabdoid tumor or whether a rhabdoid morphology represents a nonspecific phenotype which can occur in a variety of neoplasms.
  • In this study, we stained a series of adult uterine neoplasms with a prominent component of rhabdoid cells with the Baf 47 antibody which detects INI1; we aimed to ascertain whether these are related to childhood malignant rhabdoid tumor.
  • Neoplasms included were an undifferentiated sarcoma consisting entirely of rhabdoid cells, 2 carcinosarcomas with a mesenchymal component composed entirely of rhabdoid cells, and 3 uterine tumors resembling ovarian sex cord tumor with rhabdoid cells.
  • In all cases, there was positive nuclear staining of the rhabdoid cells with Baf 47, suggesting an absence of gene deletion or mutation and that these neoplasms are not related to childhood malignant rhabdoid tumor.
  • In adults, we suggest that a diagnosis of malignant rhabdoid tumor should not be made without genetic confirmation or loss of immunohistochemical expression of Baf 47.
  • In the absence of these, an attempt should be made to classify such tumors on the basis of any associated parent neoplasm and/or immunohistochemical or ultrastructural evidence of specific differentiation.
  • We reviewed uterine neoplasms with a rhabdoid phenotype.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / metabolism. DNA-Binding Proteins / metabolism. Rhabdoid Tumor / metabolism. Rhabdoid Tumor / pathology. Transcription Factors / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gene Deletion. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Mutation / genetics. Phenotype. Retrospective Studies

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317218.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


82. Rodriguez FJ, Scheithauer BW, Perry A, Oliveira AM, Jenkins RB, Oviedo A, Mork SJ, Palmer CA, Burger PC: Ependymal tumors with sarcomatous change ("ependymosarcoma"): a clinicopathologic and molecular cytogenetic study. Am J Surg Pathol; 2008 May;32(5):699-709
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymal tumors with sarcomatous change ("ependymosarcoma"): a clinicopathologic and molecular cytogenetic study.
  • Gliosarcomas are uncommon primary tumors of the central nervous system defined as exhibiting both glial and sarcomatous components.
  • Sarcomatous change occurring in ependymal tumors is rare.
  • The tumors were located in the parieto-occipital (n=2), temporal (n=1), parietal (n=1), frontal (n=1), and occipital lobes (n=1), as well as the lateral ventricles (n=2), insula (n=1), cerebellopontine angle (n=1), and fourth ventricle/cerebellopontine angle (n=1).
  • At presentation, the sarcomatous component was noted in 6 (of 10) cases and the ependymal element was grade III in 7 and grade II in 3 tumors, respectively.
  • Although rare, ependymal neoplasms must be included among the gliomas prone to undergo sarcomatous change and we propose the term "ependymosarcoma" for these tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / secondary. Fibrosarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chromosome Aberrations. Combined Modality Therapy. DNA, Neoplasm / analysis. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Survival Rate


83. Ferrucci PF, Vanazzi A, Tesoriere G, Ferrari M, Bartolomei M, Rocca P, Cremonesi M, Paganelli G, Martinelli G: Cerebrospinal fluid diffusion of Zevalin after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement. Ann Oncol; 2005 Oct;16(10):1710-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid diffusion of Zevalin after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972281.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / ibritumomab tiuxetan
  •  go-up   go-down


84. Patrick TA, Giannini C, Ebersold MJ, Link MJ: Iatrogenic cerebellar implantation of a vestibular schwannoma. Case report. J Neurosurg; 2006 Mar;104(3):452-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic seeding or iatrogenic implantation of numerous types of primary central nervous system tumors, typically along cerebrospinal fluid pathways, is a frequently described albeit rare phenomenon and has never been reported in association with vestibular schwannoma (VS).
  • Five years later--10 years after initial presentation--follow-up imaging revealed a 1-cm recurrence of the VS and a separate 2.2-cm tumor in the inferior cerebellar parenchyma with surrounding edema.
  • Both tumors were removed without complication by reopening the previous retrosigmoid craniotomy.
  • Histological evaluation of these tumors revealed features typical of VS and similar to those of the tissue obtained from the two prior resections.
  • Given the similarities among these tumors in pathological appearance and mitotic index, the presence of the intraparenchymal cerebellar schwannoma was probably due to intraoperative iatrogenic implantation.
  • [MeSH-major] Cerebellar Neoplasms / etiology. Neuroma, Acoustic / etiology
  • [MeSH-minor] Adult. Cerebellopontine Angle / pathology. Humans. Iatrogenic Disease. Male. Mitotic Index. Neoplasm Recurrence, Local / surgery

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16572663.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Paniago AM, de Oliveira PA, Aguiar ES, Aguiar JI, da Cunha RV, Leme LM, Salgado PR, Domingos JA, Ferraz RL, Chang MR, Bóia MN, Wanke B: Neuroparacoccidioidomycosis: analysis of 13 cases observed in an endemic area in Brazil. Trans R Soc Trop Med Hyg; 2007 Apr;101(4):414-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lungs were involved in 11 cases (84.6%) and only two cases had mycosis limited to the central nervous system.
  • Co-morbidity was observed in four patients (malignant neoplasm in three and diabetes mellitus in one).
  • [MeSH-major] Central Nervous System Fungal Infections / diagnosis. Paracoccidioidomycosis / diagnosis
  • [MeSH-minor] Adult. Antifungal Agents / therapeutic use. Follow-Up Studies. Gait Disorders, Neurologic / microbiology. Headache / microbiology. Humans. Male. Middle Aged. Paresis / microbiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011605.001).
  • [ISSN] 0035-9203
  • [Journal-full-title] Transactions of the Royal Society of Tropical Medicine and Hygiene
  • [ISO-abbreviation] Trans. R. Soc. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


86. Wadasadawala T, Trivedi S, Gupta T, Epari S, Jalali R: The diagnostic dilemma of primary central nervous system melanoma. J Clin Neurosci; 2010 Aug;17(8):1014-1017
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic dilemma of primary central nervous system melanoma.
  • Melanomas are malignant neoplasms of melanocytes developing predominantly in the skin, but occasionally arising from eyes, mucous membranes, and the central nervous system (CNS).
  • The CNS can be affected by a spectrum of melanocytic lesions ranging from diffuse neurocutaneous melanosis, to a focal and benign neoplasm (melanocytoma), and to an overtly malignant tumor (melanoma).
  • Primary melanocytic lesions involving the CNS are typically concentrated in the perimedullary and high cervical region.
  • Primary CNS melanoma cannot be reliably distinguished from metastatic melanoma on neuroimaging and histopathological characteristics alone: its diagnosis is established only after exclusion of secondary metastatic disease from a cutaneous, mucosal or retinal primary.
  • We present two patients with primary CNS melanoma and discuss relevant issues, available treatment options, and expected outcomes.
  • Awareness of disease spectrum and clinico-biological differences may be used to guide therapeutic decision-making for a patient with a proven or suspected primary CNS melanoma.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebellopontine Angle / pathology. Melanoma / pathology. Parietal Lobe / pathology
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20627582.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


87. Samaras V, Stamatelli A, Samaras E, Stergiou I, Konstantopoulou P, Varsos V, Judkins AR, Biegel JA, Barbatis C: Atypical teratoid/rhabdoid tumor of the central nervous system in an 18-year-old patient. Clin Neuropathol; 2009 Jan-Feb;28(1):1-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the central nervous system in an 18-year-old patient.
  • OBJECTIVE: Atypical teratoid/rhabdoid tumors are aggressive neoplasms of the central nervous system occurring mainly in the early childhood and rarely in adults.
  • We described a case of this tumor in an 18-year-old male patient without previous medical history.
  • MATERIAL AND METHODS: The neoplasm was localized in the right frontotemporal area of the brain and was totally excised.
  • The histological and immunohistochemical features of the neoplasm were assessed, while sequencing analysis as well as interphase fluorescence in situ hybridization (FISH) were performed.
  • INI1 immunostaining demonstrated diffuse loss of nuclear INI1 expression in tumor cells.
  • Taken together, the results were consistent with a diagnosis of atypical teratoid/rhabdoid tumor (ATRT).
  • To our knowledge, this is the eighth case of an ATRT reported in an adult patient having genetic confirmation and the first one in which the tumor is, partly, localized in the right temporal area of the brain.
  • This unusual presentation underlines the necessity of considering this devastating neoplasm in the differential diagnosis of malignant brain tumors of young adults.

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Neuropathol. 2006 Mar-Apr;25(2):81-5 [16550741.001]
  • [Cites] Neuropathology. 2006 Feb;26(1):57-61 [16521480.001]
  • [Cites] J Neurooncol. 2007 Sep;84(2):217-22 [17431546.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):321-30 [18369529.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):49-55 [17377740.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1114-8 [10632935.001]
  • [Cites] No Shinkei Geka. 2000 Apr;28(4):351-8 [10769834.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):156-62 [11230702.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] Pediatr Neurosurg. 2002 Aug;37(2):64-70 [12145514.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] Neurol India. 2003 Jun;51(2):273-4 [14571026.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Acta Neurochir (Wien). 2004 Sep;146(9):1033-8; discussion 1038 [15340816.001]
  • [Cites] Urol Radiol. 1985;7(1):42-4 [2984819.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):81-5 [7679853.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2002-6 [7801128.001]
  • [Cites] Semin Diagn Pathol. 1995 Aug;12(3):233-48 [8545590.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Can J Neurol Sci. 1996 Nov;23(4):257-63 [8951203.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):223-7 [9024522.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):203-6 [9671307.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):74-9 [9892189.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):247 [10477033.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):23-8 [15779233.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] J Neurooncol. 2005 Sep;74(3):311-9 [16132523.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):907-15 [16221059.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):309-13 [16195799.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43 [16406394.001]
  • (PMID = 19216214.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA046274-17A2; United States / NCI NIH HHS / CA / R01 CA046274; United States / NCI NIH HHS / CA / CA 46274; United States / NCI NIH HHS / CA / R01 CA046274-17A2
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Other-IDs] NLM/ NIHMS113796; NLM/ PMC2712356
  •  go-up   go-down


88. Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C: [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Orv Hetil; 2009 Oct 18;150(42):1937-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic management of central nervous system lymphomas in a single hematological institute].
  • Primary central nervous system lymphoma is defined as an extranodal lymphoma arising in the central nervous system in the absence of systemic disease.
  • AIMS: In this retrospective survey we analyzed the result of combined treatment (systemic and intrathecal chemotherapy followed by consolidation radiotherapy) in patients with primary or relapsed central nervous system lymphomas diagnosed and treated in our hematological department between 1998-2009.
  • PATIENTS AND METHODS: During this period (mean follow-up of 13.2 months) from 427 patients with newly diagnosed non-Hodgkin's lymphomas, 22 primary central nervous system lymphoma was diagnosed (5.15%, 16 cerebral and 6 spinal cord lymphoma cases).
  • All central nervous system lymphoma specimens taken with neurosurgical resection or stereotaxic biopsies were confirmed histopathologically.
  • In case of partial response, boost irradiation for the tumor bed was also given.
  • CONCLUSION: In primary central nervous system lymphoma, basic treatment HD methotrexate together with intrathecal combination of methotrexate + cytosin-arabinosid + dexamethasone followed by whole-brain irradiation of at least 30 Gy could produce a medium response rate in our study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Cranial Irradiation. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Epidural Space. Female. Humans. Hungary / epidemiology. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Positron-Emission Tomography. Prednisone / administration & dosage. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Rituximab. Salvage Therapy / methods. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19812012.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


89. Jalali R, Srinivas C, Nadkarni TD, Rajasekharan P: Suprasellar haemangiopericytoma--challenges in diagnosis and treatment. Acta Neurochir (Wien); 2008 Jan;150(1):67-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Haemangiopericytomas of central nervous system (CNS) were first defined as a separate entity in 1942.
  • Previously they were either considered to be a histological variant of an angioblastic meningioma or a distinctive mesenchymal neoplasm.
  • [MeSH-major] Central Nervous System Cysts / diagnosis. Central Nervous System Cysts / therapy. Hemangiopericytoma / diagnosis. Hemangiopericytoma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Sella Turcica
  • [MeSH-minor] Adult. Craniotomy. Diagnosis, Differential. Humans. Male. Middle Aged. Neoplasm, Residual. Pituitary Neoplasms / diagnosis. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176777.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 18
  •  go-up   go-down


90. Volpp PB, Han K, Kagan AR, Tome M: Outcomes in treatment for intradural spinal cord ependymomas. Int J Radiat Oncol Biol Phys; 2007 Nov 15;69(4):1199-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Spinal cord ependymomas are rare tumors, accounting for <2% of all primary central nervous system tumors.
  • This study assessed the treatment outcomes for patients diagnosed with spinal cord ependymomas within the Southern California Kaiser Permanente system.
  • CONCLUSIONS: The results of our study indicate that en bloc gross total resection should be the initial treatment, with radiotherapy reserved primarily for postoperative cases with unfavorable characteristics such as residual tumor, anaplastic histologic features, or piecemeal resection.
  • [MeSH-major] Ependymoma / radiotherapy. Ependymoma / surgery. Spinal Cord Neoplasms / radiotherapy. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Radiotherapy, Adjuvant. Salvage Therapy / methods. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689025.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Winterton RI, Wilks DJ, Chumas PD, Russell JL, Liddington MI: Surgical correction of midline nasal dermoid sinus cysts. J Craniofac Surg; 2010 Mar;21(2):295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasal dermoid sinus cysts are unsightly, prone to infection, and, importantly, may communicate with the central nervous system.
  • [MeSH-major] Dermoid Cyst / surgery. Nose Diseases / surgery. Nose Neoplasms / surgery. Respiratory Tract Fistula / surgery
  • [MeSH-minor] Adult. Child. Child, Preschool. Cohort Studies. Craniotomy / methods. Dura Mater / surgery. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / surgery. Postoperative Complications. Predictive Value of Tests. Rhinoplasty. Surgical Flaps. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20186096.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Koukourakis GV, Kouloulias V, Zacharias G, Papadimitriou C, Pantelakos P, Maravelis G, Fotineas A, Beli I, Chaldeopoulos D, Kouvaris J: Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules; 2009;14(4):1561-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) which have a combined incidence of 5-8/100,000 population, represent the most common primary central nervous system tumors.
  • Temozolomide is a new drug which has shown promise in treating malignant gliomas and other difficult-to-treat tumors.
  • In addition, in clinical studies, temozolomide consistently demonstrates reproducible linear pharmacokinetics with approximately 100% p.o. bioavailability, noncumulative minimal myelosuppression that is rapidly reversible, and activity against a variety of solid tumors in both children and adults.
  • At the present time temozolomide is approved in the United States for the treatment of adult patients with refractory anaplastic astrocytoma and, in the European Union, for treatment of glioblastoma multiforme showing progression or recurrence after standard therapy.
  • Temozolomide's characteristics which make it a candidate for a wide range of clinical testing to evaluate the potential of combination treatments in different tumor types are its predictable bioavailability and minimal toxicity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma. Brain Neoplasms. Dacarbazine / analogs & derivatives. Glioblastoma
  • [MeSH-minor] Combined Modality Therapy. Drug Resistance, Neoplasm. Humans. MEDLINE. Molecular Structure. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384285.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 67
  •  go-up   go-down


93. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM: Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol; 2008 Jul;19(7):1242-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
  • BACKGROUND: The purpose of this retrospective study was to determine, in a cohort of patients with breast cancer and central nervous system (CNS) metastases, the effect of trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive disease and to compare this with that of patients with HER2-negative disease.
  • METHODS: Five hundred and ninety-eight patients with invasive breast cancer, CNS metastases and known HER2 status were identified.
  • Time to CNS metastases and survival after CNS metastases were estimated by the Kaplan-Meier method, and Cox models were fitted to determine the association between HER2 status, trastuzumab treatment and outcomes after adjustment for other patient characteristics.
  • RESULTS: In the multivariable model, patients with HER2-negative disease [Hazard ratio (HR) 1.50, 95% confidence interval (CI) 1.15-1.95, P = 0.003] and patients with HER2-positive disease who did not receive trastuzumab (HR 2.13, 95% CI 1.51-3.00, P < 0.0001) had shorter times to CNS metastases compared with patients with HER2-positive disease who had received trastuzumab as first-line therapy for metastases.
  • Furthermore, patients with HER2-negative disease (HR 1.66, 95% CI 1.31-2.12, P < 0.0001) and patients with HER2-positive disease who had never received trastuzumab (HR 1.34, 95% CI 0.78-2.30, P = 0.28) had an increased hazard of death compared with patients with HER2-positive disease who had received trastuzumab before or at the time of CNS metastases diagnosis.
  • CONCLUSION: In our cohort of patients with breast cancer and CNS metastases, patients with HER2-positive disease treated with trastuzumab had longer times to development of and better survival from CNS metastases compared with patients with HER2-positive disease who had never received trastuzumab and patients with HER2-negative breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334512.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23CA121994-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


94. AIRTUM Working Group: [Italian cancer figures, report 2010: Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients]. Epidemiol Prev; 2010 Sep-Dec;34(5-6 Suppl 2):1-188
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients aged 75 years or more, the proportions of prevalent cases were 19%in males and 13%in females, and 10%between 60 and 75 years of age in both genders.More than half a million Italian women were alive with a breast cancer diagnosis (42%of women with a neoplasm), followed by women with cancers of the colonrectum (12%), corpus uteri (7%), thyroid (5%), and cervix uteri (4%).
  • Percentages of long-term survivors higher than 70% were reported for cancers of the cervix uteri (82% at five years, and 55% at 15 years from diagnosis), Hodgkin lymphoma, testis, brain and central nervous system, bone and connective tissue.
  • [MeSH-major] Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Databases, Factual. Epidemiologic Studies. Female. Humans. Infant. Italy / epidemiology. Male. Middle Aged. Prevalence. Registries. Remission Induction. Survivors / statistics & numerical data. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220827.001).
  • [ISSN] 1120-9763
  • [Journal-full-title] Epidemiologia e prevenzione
  • [ISO-abbreviation] Epidemiol Prev
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Investigator] Guzzinati S; Dal Maso L; De Angelis R; De Paoli A; Buzzoni C; Crocetti E; Bucchi L; Casella C; Cuccaro F; Fusco M; Luminari S; Madeddu A; Mangone L; Patriarca S; Piffer S; Stracci F; Tagliabue G; Tumino R; Zappa M; Capocaccia R; Ferretti S; Mazzoleni G; Bellú F; Tschugguel B; De Valiere E; Facchinelli G; Falk M; Dal Cappello T; Giacomin A; Vercellino PC; Andreone S; Busato A; Marzola L; Migliari E; Carletti N; Nenci I; Caldarella A; Corbinelli A; Giusti F; Intrieri T; Manneschi G; Nemcova L; Romeo G; Sacchettini C; Paci E; Serraino D; Angelin T; Bidoli E; de Dottori M; De Santis E; Forgiarini O; Zucchetto A; Zanier L; Vercelli M; Orengo MA; Marani E; Puppo A; Celesia MV; Cogno R; Manenti S; Garrone E; Quaglia A; Pannozzo F; Busco S; Rashid I; Ramazzotti V; Cercato MC; Battisti W; Sperduti I; Macci L; Bugliarello E; Bernazza E; Tamburo L; Rossi M; Curatella S; De Francesco C; Tamburrino S; Bisanti L; Autelitano M; Randi G; Ghilardi S; Leone R; Filipazzi L; Bonini A; Giubelli C; Federico M; Artioli ME; Valla K; Braghiroli B; Cirilli C; Pirani M; Ferrari L; Bellatalla C; Fusco M; Panico M; Perrotta C; Vassante B; Traina A; Carruba G; Cusimano R; Amodio R; Dolcemascolo C; Staiti R; Zarcone M; Michiara M; Bozzani F; Sgargi P; Cilia S; La Rosa MG; Cascone G; Frasca G; Giurdanella MC; Martorana C; Morana G; Nicita C; Rollo P; Ruggeri MG; Sigona A; Spata E; Vacirca S; Di Felice E; Pezzarossi A; Caroli S; Pellegri C; Vicentini M; Storchi C; Cavuto S; Costa J; Falcini F; Colamartini A; Balducci C; Ravegnani M; Vitali B; Cordaro C; Caprara L; Giuliani O; Giorgetti S; Salvatore S; Palumbo M; Vattiato R; Ravaioli A; Foca F; Rinaldi E; Donato A; Iannelli A; Senatore G; Zevola A; Budroni M; Cesaraccio R; Pirino D; Carboni D; Fiori G; Soddu M; Mameli G; Mura F; Contrino ML; Tisano F; Sciacca S; Muni A; Mizzi M; Russo M; Tessandori R; Ardemagni G; Gianola L; Maspero S; Annulli ML; Moroni E; Roberto G; Zanetti R; Rosso S; Prandi R; Sobrato I; Gilardi F; Busso P; Franchini S; Gentilini MA; Battisti L; Cappelletti M; Moser M; La Rosa F; D'Alò D; Scheibel M; Costarelli D; Spano F; Rossini S; Santucci C; Petrinelli AM; Solimene C; Bianconi F; Brunori V; Crosignani P; Contiero P; Preto L; Tittarelli A; Maghini A; Codazzi T; Frassoldi E; Gada D; Costa E; di Grazia L; Zambon P; Baracco M; Bovo E; Dal Cin A; Fiore AR; Greco A; Monetti D; Rosano A; Stocco C; Tognazzo S; Donato F; Limina RM; Adorni A; Andreis P; Zani G; Piovani F; Salvi O; Puleio M; Vitarelli S; Antonini S; Candela G; Pappalardo G; Scuderi T; Lottero B; Ribaudo M; Ricci P; Guarda L; Gatti L; Bozzeda A; Dall'Acqua M; Pironi V; Sutera Sardo A; Mazzei A; Sirianni N; Lavecchia AM; Mancuso P; Usala M; Pala F; Sini GM; Pintori N; Canu L; Demurtas G; Doa N; Pisani P; Pastore G; Magnani C; Terracini B; Cena T; Alessi D; Baussano I; Merletti F; Maule M; Mosso ML; Nonnato M; Rasulo A; Richiardi L; Zuccolo L; Pivetta E; Dalmasso P; Macerata V; Ponz de Leon M; Domati F; Rossi G; Goldoni CA; Rossi F; De Gaetani C; Benatti P; Roncucci L; Di Gregorio C; Pedroni M; Pezzi A; Maffei S; Mariani F; Borsi E; Cocchioni M; Pascucci C; Gennaro V; Lazzarotto A; Benfatto L; Mazzucco G; Montanaro F
  •  go-up   go-down


95. Lewis KD, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, Baron A, Russ P, Gonzalez R: A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest; 2005;23(4):303-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a site of frequent relapse is in the central nervous system (CNS).
  • Temozolomide is an oral alkylating agent that has equivalent activity to dacarbazine, but it has the advantage of CNS penetration.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Eye Neoplasms / drug therapy. Eye Neoplasms / mortality. Eye Neoplasms / pathology. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Interleukin-2 / administration & dosage. Middle Aged. Neoplasm Metastasis. Reproducibility of Results. Skin Neoplasms / drug therapy. Skin Neoplasms / mortality. Skin Neoplasms / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100942.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA46934
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 85622-93-1 / temozolomide
  •  go-up   go-down


96. Zhou J, Li NY, Zhou XJ, Zhou HB, Wu B, Jiang SJ, Ma HH, Zhang RS: [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system].
  • OBJECTIVE: To study clinicopathologic features, diagnosis, treatment and prognosis of von Hippel-Lindau (VHL) syndrome-related and sporadic hemangioblastomas of the central nervous system (CNS-HB).
  • METHODS: Histopathological, ultrastructural, immunohistochemical (EnVision method) and clinical features of 21 VHL syndrome and 63 sporadic CNS-HB cases were studied with correlation of the available follow-up information.
  • RESULTS: Twenty-one VHL patients accompanied with a total of 87 CNS-HBs, including one patient of developing 12 HBs within 13 years.
  • There were 10 patients presenting other lesions related to VHL, including 6 retinal HBs, 4 pancreatic tumors (endocrine tumor and microcystic cystadenoma), 1 clear renal cell carcinoma, 4 renal cysts and 1 endolymphatic sac tumor.
  • One patient developed 5 different tumors related to VHL within a period of 4 years.
  • In the 63 cases of sporadic CNS-HB (34 male and 29 female), the mean age was 43.0 years.
  • Histologically, the tumors showed large and vacuolated stromal cells.
  • Some tumors showed atypical nuclei.
  • Tumor cells of HB stained positive for vimentin, EGFR, Inhibin alpha and D2-40, but negative for CD34 and CD68.
  • The syndrome is characterized by development of various benign and malignant tumors.
  • The most common tumor is CNS-HB, which occurs predominantly in the cerebellum.
  • Patients with VHL syndrome tend to present at a younger age than patients with sporadic CNS-HBs, and VHL related HB occurs more predominantly in the brain stem and spinal cord.
  • Prognosis of CNS-HB patients is not correlated with the nuclear atypicality, expression for Ki-67 and involvement of the brain tissue.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Hemangioblastoma / pathology. von Hippel-Lindau Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Child. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Inhibins / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Receptor, Epidermal Growth Factor / metabolism. Retinal Neoplasms / metabolism. Retinal Neoplasms / pathology. Retinal Neoplasms / surgery. Survival Analysis. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450758.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Vimentin; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


97. Guo HY, Zhao XM, Cao JN, Hu XC, Yin JL, Hong XN, Li J: [Prognosis of primary non-Hodgkin's lymphoma of the breast]. Zhonghua Zhong Liu Za Zhi; 2008 Mar;30(3):200-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central nervous system involvement (RR = 1.107, P = 0.005) was a negative independent prognostic factor for PFS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / therapeutic use. Breast Neoplasms, Male / drug therapy. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radiotherapy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756936.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


98. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J: Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res; 2008;27:85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Gliomas represent the most frequent neoplasm of the central nervous system.
  • Unfortunately, surgical cure of it is practically impossible and their clinical course is primarily determined by the biological behaviors of the tumor cells.
  • RESULTS: Immunohistochemical analysis with anti-Nestin and anti-CD133 antibodies revealed dense and spotty staining in the tumor cells and their expression levels became significantly higher as the glioma grade advanced (p < 0.05).
  • A combined detection of Nestin/CD133 co-expression may benefit us in the prediction of aggressive nature of this tumor.
  • [MeSH-major] Antigens, CD / biosynthesis. Biomarkers, Tumor / biosynthesis. Brain Neoplasms / metabolism. Glioma / metabolism. Glycoproteins / biosynthesis. Intermediate Filament Proteins / biosynthesis. Neoplastic Stem Cells / metabolism. Nerve Tissue Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Nestin. Peptides. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Exp Neurol. 2000 Feb;161(2):585-96 [10686078.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5 [11121071.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2387-95 [11489817.001]
  • [Cites] J Physiol Paris. 2002 Jan-Mar;96(1-2):81-90 [11755786.001]
  • [Cites] Exp Neurol. 2002 Mar;174(1):89-95 [11869037.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):228-33 [15102349.001]
  • [Cites] J Neurooncol. 2004 Jun;68(2):113-21 [15218947.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Radiother Oncol. 1991 Feb;20(2):99-110 [1851573.001]
  • [Cites] Lab Invest. 1992 Mar;66(3):303-13 [1538585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12425-30 [9356465.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):656-70 [15316624.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):222-3 [15677549.001]
  • [Cites] Stem Cells. 2005 Jun-Jul;23(6):791-804 [15917475.001]
  • [Cites] BMC Cancer. 2006;6:32 [16457706.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):485-92 [16418842.001]
  • [Cites] Acta Neuropathol. 2006 Mar;111(3):272-7 [16538520.001]
  • [Cites] Neurosci Lett. 2006 May 29;400(1-2):80-5 [16529857.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):227-33 [16826367.001]
  • [Cites] Surg Neurol. 2007 Aug;68(2):133-43; discussion 143-4 [17537489.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6970-7 [18056172.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):31-45 [17611714.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):467-73 [17873113.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):370-7 [18371181.001]
  • (PMID = 19108713.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Peptides
  • [Other-IDs] NLM/ PMC2633002
  •  go-up   go-down


99. Vyberg M, Ulhøi BP, Teglbjaerg PS: Neuronal features of oligodendrogliomas--an ultrastructural and immunohistochemical study. Histopathology; 2007 Jun;50(7):887-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Central Nervous System Neoplasms / pathology. Neurons / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. DNA, Neoplasm / analysis. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Microscopy, Electron, Transmission. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17543079.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


100. Corti M, Villafañe Fioti MF, Lewi D, Schtirbu R, Narbaitz M, de Dios Soler M: [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.
  • The median age was 42 years and the median CD4 T cell count was 87 cells/uL at the time of the diagnosis of neoplasm.
  • The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.
  • Primary duodenal lymphoma was the only Burkitt lymphoma of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis






Advertisement